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G protein coupled receptor (GPCR) kinases (GRKs) phosphorylate activated
heptahelical receptors, leading to their uncoupling from G proteins and downregulation.
The desensitization of GPCRs is critical to render cells responsive to further stimuli and
if not regulated can result in many pathophysiological processes including heart
abnormalities and hypertension. How GRKs recognize and are activated by GPCRs are
not known, in part because the critical N-terminus and the kinase C-terminal extension
were not resolved in GRK2 and GRK6 structures. The long-term goal of this project was
to address this question by structural analysis of rhodopsin kinase (also known as GRK1),
which represents a model system for studying phosphorylation-dependent desensitization
of activated GPCRs. Herein we report structures of GRK1 from six crystal forms that
represent three distinct nucleotide-ligand binding states. One of the (Mg2+)2·ADP·GRK1
structures is the most high-resolution structure (1.85 Å) of a GRK to date. In one
(Mg2+)2·ATP·GRK1 structure, almost the entire N-terminal region (residues 5-30) is
observed.  In addition, different segments of the kinase C-terminal extension are ordered
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in the various nucleotide-bound structures. Together, these two elements form a putative
receptor-docking site adjacent to the hinge of the kinase domain. Based on these
structures, a model is proposed for how GRK1 interacts with activated rhodopsin and
how rhodopsin binding in turn could activate the kinase. Two novel phosphorylation sites
were also identified at the N-terminus. The physiological role of phosphorylation sites
and the extensive dimerization interface mediated by the regulator of G protein signaling
(RGS) homology domain of GRK1 was assessed using site-directed mutagenesis.
In addition to mediating interaction with activated GPCRs, the N-terminus of
GRKs also forms a binding site for calcium sensing proteins. Although its physiological
significance is debated, the structures of these complexes could lend further insights into
the conformation of the N-terminus of GRKs. The second chapter deals with attempts to
isolate Ca2+·recoverin·GRK1 and Ca2+·calmodulin·GRK6 complexes. Finally, the RH
domain of GRK2 binds Gαq, Gα11, and Gα14 subunits thereby blocking their interactions
with the downstream effectors. The third chapter involves attempts to isolate a complex
of GRK6 and Gα16, a member of Gαq family.
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Chapter 1: Structure Determination of GRK1
INTRODUCTION
G Protein Coupled Receptor (GPCR) Signaling
G protein coupled receptors (GPCRs) are ubiquitous proteins that transduce
signals to the cell interior allowing cells to respond to extracellular stimuli.  The receptors
are responsive to a wide-range of stimuli that range from a photon of light, pheromones
and neurotransmitters, to peptide hormones. The signaling through GPCRs (Fig. 1) is
mediated by activation of guanine nucleotide binding (G) protein subunits that further
regulate downstream effectors that propagate the signal within the cell. The activated
GPCRs must be desensitized in a regulated manner in order for cells to remain responsive
to their environment. The two proteins that play a key role in this process are GPCR
kinases (GRKs) and arrestins. Activated receptors are first phosphorylated by GRKs and
then bound by arrestins to quench the signaling.
GPCRs form one of the largest superfamilies of membrane proteins. In humans
the estimated number of GPCRs is ~950 [1], which corresponds to about 5% of the
genes. GPCRs regulate diverse physiological processes that range from sensations of
sight, smell and taste to endocrine function. Malfunctions associated with receptor
function or regulation have been linked to diseases such as hypertension, obesity, heart
abnormalities and blindness [2]. Their crucial role in regulation of cellular functions
makes them a target of about 50% of drugs currently available in market [3, 4].
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Figure 1: G protein coupled receptor signaling in retina.   
(a) A photon of light triggers isomerization of chromophore 11-cis-retinal to all-trans-retinal,
leading to a conformational change that results in activation of rhodopsin (Rho*). Rho* then
activates transducin (Gαt) by catalyzing exchange of GTP for GDP on the Gα subunit, which
then dissociates from Gβγ and activates phosphodiesterase. The resulting drop in the cGMP
levels results in closure of cGMP-gated cation channels causing hyperpolarization of the
membrane, inhibition of the release of neurotransmittors and signaling to the brain. (b) Rhodopsin
kinase initiates desensitization of Rho* by phosphorylating its cytoplasmic tail. Phosphorylated
Rho* is bound by arrestin, which blocks the interaction of receptor with G proteins and quenches
signaling. RGS9 hydrolyzes GTP on the Gα subunit and GDP·Gα then re-associates with the Gβγ
subunits. Drop in Ca2+ levels in the cytoplasm (associated with closure of cGMP-gated channels)
activates guanylate cyclase activating proteins, which activate guanylate cyclase resulting in
resynthesis of cGMP and opening of channels.
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Rhodopsin Structure
GPCRs are integral membrane proteins that possess seven transmembrane helices,
hence the name 7TM or heptahelical receptors. The extracellular side forms the ligand-
binding surface while the cytoplasmic surface forms a binding site for the signaling
proteins (Fig. 2). Its availability (~ 0.5-1 mg/eye) and relative ease of purification make
rhodopsin, a retinal photoreceptor, one of the most well-studied GPCRs. Rhodopsin is the
first GPCR to have its primary sequence deciphered [5, 6], to be purified to homogeneity
and is the first receptor to have a crystal structure reported [7]. It is the only receptor for
which crystal structures are available representing the conformations of both the active
[8] and inactive [9] states.  The functional unit of rhodopsin was initially characterized to
be a monomer [10] but recent biophysical and biochemical studies suggest that rhodopsin
can form dimers and other higher-order oligomers [11-14]. Oligomerization is seen in
other GPCRs as well [14-16]. The physiological relevance of receptor dimers (or
oligomers) is debated but it could play a role in receptor biosynthesis, trafficking and
internalization.
Rhodopsin is composed of the apoprotein opsin, which is covalently linked to the
chromophore 11-cis-retinal through Schiff’s base linkage to the ε-amino group of
Lys216. Upon stimulation by a photon of light, the chromophore and Lys216 become
deprotonated to form the photo-activated state of rhodopsin (Rho* or metarhodopsin II or
MetaII). The conformational change upon activation may not be dramatic [8]. However,
in the active conformation the cytoplasmic surface of rhodopsin becomes accessible to
signaling proteins. The heterotrimeric G proteins, GRKs and arrestins are protein families
that can specifically recognize and bind to the activated form of receptors.
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Figure 2: Crystal structure of a photoactivated intermediate of rhodopsin.
In this model (PDB code: 2I37) ribbons are colored cyan, sheets wheat and loops grey.
Oxygen atoms are colored red and nitrogens blue. The helices I (αI and αI’), II (αII and
αII’) and the cytoplasmic helix 8 (H8 and H8’), which mediate dimer formation (~800 Å2
buried surface area) are colored slate. In this model the Schiff’s base linkage between the
Lys296 residue and the chromophore was predicted to be deprotonated based on the
analysis of the retinal content and the absorption maxima of these light-exposed crystals.
Thus, the structure appears to represent a photoactivated intermediate of rhodopsin [8].
Compared to the structure of inactivated rhodopsin [9], the transmembrane helices do not
undergo a dramatic conformational change. The cytoplasmic loops that are thought to
interact with Gα subunits, GRKs and arrestins are also not ordered. The grey region
represents the plasma membrane.
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The Discovery of GRKs
The phosphorylation of rhodopsin was first described in the early 1970s when it
was shown that a rod outer segment (ROS) preparation undergoes phosphorylation in the
presence of radiolabeled-ATP. The incorporation of phosphates was found to be
stimulated in the presence of light [17] and was later demonstrated to be occurring in vivo
as well [18, 19]. It was suggested that light-enhanced phosphorylation was resulting from
conformational changes in rhodopsin and not because of stimulation of the kinase [20].
This was followed by purification of a protein kinase from ROS that was specific for
photobleached rhodopsin [21, 22]. Subsequent studies focused on understanding the
affects of phosphorylation of rhodopsin, the relation of visual “excitation” to other
processes such as membrane permeability and identification of the various steps involved
in the pathway. The term “rhodopsin kinase” was coined owing to the specificity for
rhodopsin. Over the next three decades the kinase has been extensively investigated. This
includes cloning and purification of rhodopsin kinase [23-32], identification of post-
translational modification such as isoprenylation [33-36], and autophosphorylation [25,
37-39] and determination of substrate specificity and regulation of activity [25, 30, 40-
52]. Being the first member of the family of kinases that specifically bind to and
phosphorylate the activated form of a GPCR, rhodopsin kinase (RK) is also known as
GPCR kinase 1 or GRK1.
The GRK Family
GRKs are Ser/Thr protein kinases that specifically recognize and phosphorylate
the activated form of GPCRs. There are seven members of the mammalian GRK family
[53], which are grouped into three sub-families based on sequence homology. The GRK1
sub-family includes GRK1 and GRK7; GRK2 sub-family includes GRK2 and GRK3;
and the GRK4 sub-family includes GRK4, GRK5 and GRK6. The GRK2 sub-family and
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GRK6 are ubiquitously expressed. GRK1 and GRK7 are expressed in the retina and
pineal gland, GRK4 in testis, brain and kidney and GRK5 in heart, lung and retina.
GRK1: Gene Structure and Localization
The gene for human GRK1 contains seven exons and is located on chromosome
13 (13q34) [24, 54]. In retina, GRK1 is a key player in phototransduction whereas the
exact role of the kinase in pinealocytes is not clear [55, 56]. A number of
phototransduction proteins have been identified in the pineal gland indicating an
evolutionary relationship between the photoreceptors and the pineal gland. The
expression of GRK1 in retinal rod and cone cells varies in a species-specific manner and
has been linked to the daily activities of the species.
GRK1 Domain Architecture
Bovine GRK1 is produced as a precursor of 561 amino acids. The protein is post-
translationally modified by farnesylation on Cys558 with the subsequent proteolytic
cleavage of the last three residues and carboxyl-methylation of the terminal residue.
The N-terminus
The N-terminus of GRKs has been shown to be critical for receptor phosphorylation.
Point mutations and truncations of the extreme N-terminus in GRKs has been shown to
block receptor phosphorylation with no apparent affect on the phosphorylation of soluble
substrates [49]. An antibody directed against the residues 17-34 of GRK1 was shown to
block rhodopsin phosphorylation, without affecting the intrinsic kinase activity [45].
However, there is no evidence for a direct interaction between the N-terminus and the
receptors. It has been predicted that the N-terminus forms an amphipathic helix that could
mediate binding to the lipid bilayer [57]. The recent NMR structure of GRK1 N-terminal
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peptide bound to Ca2+-recoverin reveals that the residues 4-16 form an amphipathic helix
and the residues 9-11, 14 and 15 were shown to bind to a hydrophobic surface on
recoverin [58].
The Regulator of G protein Signaling (RGS) Homology (RH) domain
The residues 31-180 and 512-531 comprise a domain that is homologous to the catalytic
domain of the RGS proteins The RH domain of GRKs is homologous to the RGS
proteins sharing ~17-34 % sequence identity. In addition to the classical nine helix
bundle [59], GRKs have been shown to contain two additional helices (α10 and α11).
The kinase domain in GRKs is inserted in a loop between the α9 and α10 helices thus
splitting the RH domain into two discontinuous segments [60] (Fig. 3).
RGS proteins function as GTPase activating proteins (GAPs) for Gα subunits of
the heterotrimeric Gαβγ complex, thus adding a regulatory step to the signaling cascade.
This is accomplished by stabilization of the switch regions of the Gα protein subunit in a
transition state conformation [59]. The exact role of the RH domain in GRKs is not well
defined. However, in GRK2 the RH domain binds the Gαq subunit. The binding surface
was mapped to the helices α5 and α6 [61]. Thus, GRK2 sub-family can also regulate
signaling via phosphorylation-independent desensitization of activated GPCRs by
sequestering both Gαq and Gβγ (via the PH domain) subunits. The GRK1 and GRK4 sub-
families have not yet been shown to interact with any of the Gα subunits.
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Figure 3.  RH Domains as Protein Interaction Domains.   
(a) RGS4 (PDB code: AGR) was the first structure of an RGS protein and defined the
RGS fold of nine α helices. These are divided into “terminal” (α1-α3, α8 and α9 helices,
colored magenta) and “bundle” (α4-α7, colored slate) subdomains. The α3-α4 and α5-
α6 loops as well as the α8 helix forms the Gαi1 binding surface. The RH domain of axin
binds adenomatous polyposis coli (APC) peptide in the cleft between the α2, α3, α4 and
α7 helices [62]. (b) The RH domain of p115-RhoGEF  (PDB code: 1SHZ) contains two
additional helices (α10 and α11), which have been colored green as they are insertions to
the core RGS fold. The N-terminal helix and the β-strand (colored orange, as they are not
a part of the RGS domain) form a Gα12/13 binding interface. (c) The structure of GRK6
(PDB code: 2ACX) reveals a third helix (α0) at the N-terminus of the RGS domain, in
addition to α10 and α11. The kinase domain is inserted between the α9 and α10 helices
in GRKs. The RH domain of GRK6 forms an extensive dimer interface in the crystals
[63]. The α5-α6 helices form the Gαq binding surface in the GRK2 sub-family [61].
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The Kinase Domain
The most conserved region of GRKs is the kinase domain (residues 181-454 in GRK1)
that belongs to a Ser/Thr protein kinase family that also includes Protein Kinase A
(PKA), G (PKG) and C (PKC) (the AGC kinases). GRK1 shares ~ 39-55% sequence
identity to the kinase domain of other members of the GRK family and ~34 % identity to
non-GRK AGC kinases. GRKs also include the “C-terminal extension” of the kinase
domain (residues 455-511 in GRK1) that is characteristic of the AGC kinase family. The
kinase C-terminal extension is believed to play important regulatory roles in other AGC
kinases [64].
The crystal structures of various AGC kinases in different nucleotide-bound states
have contributed to our current understanding of the structure of the kinase domain and
their mechanisms of activation and substrate binding. The kinase domain is comprised by
a “small lobe” (residues 181-268 in GRK1) and a “large lobe” (residues 269-454 in
GRK1) that are linked by a hinge region (Fig. 4a). The cleft between the two lobes forms
the the active site. In AGC kinases, the small and large lobes of the kinase domain
“close” upon binding adenine nucleotides, enabling a proper alignment of the catalytic
machinery in the active site. Thus far, there is no evidence of a similar conformational
change induced in GRKs upon nucleotide binding in the crystal structures of GRK2 and
GRK6.
The C-terminal extension of the kinase domain of AGC kinases contains residues
required for catalysis and is a site of interaction of cis-acting regulatory proteins. The
extension (Fig. 4A) has been divided into three structural elements. It starts with the C-
lobe (large lobe) tether (CLT, residues 300-319 in PKA) that contains a conserved PxxP
motif and has been suggested to be a SH3 binding site in PKB. Immediately following
the CLT is the active site tether (AST), which links the NLT and CLT and contributes
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residues to the nucleotide and substrate binding. The AST becomes ordered in a ligand
dependent manner and is proposed to facilitate nucleotide entry and release. At the C-
terminal end of the extension is the N-lobe (small lobe) tether (NLT, residues 340-350 in
PKA), which contains residues that interact with the β4 strand and the αB and αC helices
of the small lobe [64].
The activation of AGC kinases is also associated with multiple phosphorylation
events, which occur at sites termed the “activation loop”, the “turn motif”, and the
“hydrophobic motif”. The latter two sites reside in the C-terminal extension of the kinase
domain. The phosphorylation of activation loop by phosphoinositide-3 dependent kinase
1 (PDK1) facilitates nucleotide-binding and enhances the rate of catalysis [65]. The NLT
contains the hydrophobic motif (HM), and phosphorylation of this site stabilizes the
small lobe by securing the NLT packing against the small lobe. The HM of PKB also
serves as a docking site for PDK1 (which lacks the C-terminal extension), which then
phosphorylates the activation loop of PKB. The “turn motif”, which is phosphorylated in
PKC and PKA, stabilizes the small lobe [66]. GRKs lack equivalent serine or threonine
residues in the activation loop and the hydrophobic motif. Thus, GRKs have a distinct
mechanism of activation and use other structural features to compensate for the loss of
these motifs. In GRK1, two major autophosphorylation sites have been identified (Ser488
and Thr489) [25, 38], and these map to the “turn motif” of the AGC kinases. GRK2 bears
acidic residues at the equivalent region that could mimic a constitutively phosphorylated
state.
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Figure 4. “Open” and “Closed” Conformations of an AGC Kinase Domain.
(a) The kinase domain of PKA in the active “closed” conformation (PDB code: 1L3R) bound to
an inhibitory peptide, PKI (salmon). The small lobe comprises of antiparallel β sheets (orange)
and two prominent helices αB and αC (yellow). Large lobe is primarily α-helical. The active site
is shown here bound to ADP, Mg2+ and AlF3. The different segments of the kinase C-terminal
extension have been colored differently for emphasis. The phosphorylation sites in the activation
loop (magenta) and “turn motif” of the N lobe tether have been shown as stick models. The hinge
(magenta) connecting the two lobes allows “closure” of the domain. The hydrophobic motif is not
shown in this view. (b) The small lobes of the kinase domain in the “open” conformation (PDB
code: 1CMK) and “closed” conformation (same model as in panel a) were aligned. (c) The
molecular surface representation of the aligned kinase domain in panel b to visualize the degree
of closure upon activation. The coloring scheme is the same as in panel b.
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The C-terminus (membrane-targeting domain)
The conserved RH-kinase core found in all GRKs is followed by a membrane-targeting
domain (residues 532-561 in GRK1) that varies in a sub-family dependent manner.
GRK1 bears a consensus sequence for farnesylation with the exception of chicken GRK1,
which is modified by geranylgeranylation. A GRK1 mutant lacking the lipid-
modification is defective in membrane recruitment and is evidenced by a higher Km for
Rho* [34].
Photoreceptor Cells
In vertebrates, vision is mediated by highly specialized photoreceptors in the
retina that serve to relay the signal from photons of light to the brain in the form of an
electrical signal in a process termed phototransduction. There are about 108 photoreceptor
cells in the mammalian retina, consisting of rods and cones. In evolutionary terms, the
rods have arisen more recently than cones and are believed to have developed from cones
cells [67]. Cones operate over a broad range of illumination, are responsible for color
vision and are crucial for photopic (diurnal) vision. In contrast, rods function at relatively
lower intensities of illumination and are responsible for scotopic (night) vision. Rod cells
outnumber cones by 20-fold, and it has been argued that having an excess of rod cells
enables these photoreceptors to respond to almost every photon that the retina encounters.
The photoreceptor cells consist of three major functional regions: the outer
segment, inner segment and the synapse. The outer segments form the venue for
phototransduction. In rods, the outer segments are composed of stacks of membranes
whereas in cone cells these are simply invaginations of the plasma membrane. The discs




Photoisomerisation and Formation of Rho*
Phototransduction in vertebrate rod cells is initiated by the absorption of a photon by
rhodopsin, isomerizing its chromophore 11-cis-retinal to all-trans-retinal (Fig. 1a)
through a number of intermediates to form Rho*. These intermediates are short-lived but
can be trapped at low temperature and are distinguished based on their absorption spectra.
For example, the transition to the intermediate metarhodopsin I (MetaI) conformation
occurs in ~100 µs (λmax ~ 478 nm) and depending on the temperature, the transition from
MetaI to MetaII can take 1-10 ms (λmax ~ 380 nm). In the MetaII state, the covalently
bound all-trans-retinal is deprotonated and as a result, rhodopsin looses its color and is
said to have “bleached”. The active MetaII form of rhodopsin activates heterotrimeric G
proteins and is also phosphorylated by rhodopsin kinase.
Activation of Transducin
Rho* catalyzes nucleotide exchange on the heterotrimeric G protein transducin (Gt). The
resulting GTP-bound Gt subunit dissociates from the Gβγ subunits and binds to the
inhibitory subunit (γ) of membrane-associated cGMP phosphodiesterase 6 (PDE6), the
“effector protein”, releasing the inhibition on the catalytic α and β subunits of the
enzyme (within milliseconds).  The activated PDE6 hydrolyses cGMP resulting in a rapid
depletion of cGMP in the intradiscal space and the subsequent closure of the cGMP-gated
cation channels in the ROS plasma membrane. As a result, the flow of inward current (in
the form of Na+ and Ca2+ ions) is blocked. This leads to hyperpolarization of the
membrane, inhibition of the release of the neurotransmitter glutamate at the synapse, and
sends a signal to the brain.
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An important feature of phototransduction cascade is the amplification of signal at
each step. A photon of light activates rhodopsin and each activated rhodopsin further
activates ~100 transducin molecules. In amphibians, the turnover of transducin activation
is ~150 turnovers per second and one molecule of activated transducin in frogs causes
hydrolysis of ~600 cGMP molecules per second [69]. The end result is the closure of
cGMP-gated cation channels and hyperpolarization of the membrane.
Phototransduction Cascade: Inactivation
A rapid and efficient termination of the photoresponse (return to the “dark-state”) is
crucial for rhodopsin to remain responsive to subsequent photons and allows cells to
respond to the changes in illumination. It involves an efficient termination of each
amplification step of the signaling cascade (Fig. 1b). The rate of inactivation determines
the time course of photoresponse.
Inactivation of Rho*
Rho* is inactivated by thermal decay but, this occurs at a very slow rate (on the order of
tens of milliseconds in the retina). The ability to rapidly turn off the rhodopsin cascade is
crucial for nocturnal (scotopic) vision and involves two proteins, rhodopsin kinase and
arrestin. Rhodopsin kinase phosphorylates the cytoplasmic tail of Rho*. Phosphorylated
Rho* is then bound by arrestin and this sterically blocks the interaction of activated
receptor with G proteins (Fig. 1b). The principal sites of phosphorylation on rhodopsin
have been identified as being Ser334, Ser338 and Ser343. Both MetaI and MetaII forms
are phosphorylated by rhodopsin kinase. Opsin is also phosphorylated, and this is
stimulated in the presence of all-trans-retinal [70]. In vivo, it has been shown that
incorporation of one phosphate per Rho* leads to ~50 % reduction in transducin
activation. However, there are six potential phosphorylation sites in mice and seven in
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human and bovine rhodopsin. The multiple phosphorylation of rhodopsin is required for
efficient arrestin binding [71] and is thought to contribute to the reproducibility of the
single photon response [72].
Following the inactivation of Rho* either by thermal decay or phosphorylation by
GRK1, the all-trans-retinal is released and recycled to regenerate all-cis-retinol (in the
“retinoid cycle”) [73]. The opsin molecule is dephosphorylated by protein phosphatase
2A (PP2A) before incorporation of the chromophore 11-cis-retinol, resulting in the
regeneration of ground state rhodopsin.
Inactivation of Transducin and PDE
Activated transducin is able to hydrolyze bound GTP but at a very slow rate compared to
the time course of photoresponse. The GTPase activity of transducin is enhanced by
Regulator of G protein Signaling protein 9 (RGS9), which is bound to its obligatory
subunit Gβ5 and the membrane anchor R9AP [74] (Fig. 1b). The phosphorylation of
rhodopsin and inactivation of transducin terminates further activation of PDE, with the
inactivation of transducin being roughly 2.5 times slower than rhodopsin deactivation
[75].
Regulation by Calcium
In addition to the inactivation of the various signaling components, the restoration of
cGMP levels to the dark level is crucial for the recovery of photoresponse. This is closely
linked to the concentration of Ca2+ in the cells. The decline in the levels of cGMP in the
cytoplasm is associated with the closure of the cGMP-gated cation channels. However,
Ca2+ continues to be extruded via the Ca2+· K+/Na+ exchanger and as a result the
cytoplasmic levels of Ca2+ decline. This stimulates the synthesis of cGMP by guanylate
cyclase, which restores cGMP levels, leading to the opening of the channels.
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Regulation of GRK1
GRK1 activity is regulated at multiple levels. The most robust regulation of
GRK1 activity is mediated by the substrate Rho*, followed by phosphorylation of serine
and threonine residues within the amino terminus and the C-terminal extension of the
kinase domain. GRK1 has also been reported to be regulated by Ca2+·recoverin. This is
however, debatable (see Chapter 2).
Regulation by Rho*
The interaction of GRK1 with Rho* stimulates the kinase activity of GRK1. Peptides
derived from the C-terminal tail of rhodopsin are poor substrates (Km values are in the
mM range) but, in the presence of a C-terminally truncated rhodopsin [76], the peptide
phosphorylation is enhanced [76, 77] by over 100-fold. This suggests that Rho* docks at
site(s) distinct from the C-terminal phosphorylation sites and this docking allosterically
regulates the kinase activity. Isolated ROS have been shown to incorporate hundred fold
molar excess of phosphates per molecule of Rho* (“high-gain” rhodopsin
phosphorylation). The molecular mechanism of this phenomenon is not clear, although
once activated by Rho*, the kinase can transphosphorylate several nonactivated
rhodopsin molecules in the vicinity [78]. This has been suggested to play a role in light-
adaptation at low intensities of light.
Docking involves the cytoplasmic loops of the receptor because mutagenesis of
residues in these loops reduce receptor phosphorylation by GRK1 [79]. In addition,
peptides derived from the second and the third cytoplasmic loops of rhodopsin have been
shown to inhibit receptor phosphorylation without affecting GRK1 autophosphorylation
[41]. The sites on GRK1 responsible for receptor-mediated activation are not well
established. The N-terminus is required for efficient receptor phosphorylation [45, 49, 58]
however, it has been suggested that it is more important for binding lipid bilayer than
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mediating a direct interaction with the receptor [57]. The C-terminal extension of the
kinase domain is also implicated in receptor binding [80].
Regulation by Autophosphorylation
In addition to phosphorylating Rho*, GRK1 has been shown to autophosphorylate at 3-4
positions [25] when incubated with ATP (Km ~ 2-4 µM). GRK1 autophosphorylation is
independent of the presence of rhodopsin and the major sites have been identified as
Ser488 and Thr489. Autophosphorylation lowers the Km for ATP and is believed to
promote the dissociation from phosphorylated Rho*, perhaps due to electrostatic
repulsions. A third, and a minor, site was mapped to Ser21, which is now believed to be a
PKA site [81]. The significance of phosphorylation at this site is not well understood.
The site-directed mutagenesis studies suggest that the autophosphorylation may
determine the initial site of phosphorylation on Rho* [39]. It has also been suggested that
autophosphorylation lowers the affinity for Ca2+·recoverin [82].
GRK1 Physiology and Disease
The pigment melanin in the iris of retina provides protection against damage by
UV light. However, exposure to direct sunlight or even a continued exposure to dim light
can kill the photoreceptor cells by triggering apoptosis, as demonstrated in transgenic
mice lacking rhodopsin kinase [83]. The photoresponse is of higher amplitude and a
longer duration in these mice. Mutagenesis studies revealed that the sensitivity to light is
associated with the delayed inactivation of Rho*.
In humans, several inactivating mutations in GRK1 are known to cause Oguchi
disease, a stationary form of night-blindness that is characterized by a substantial delay in
dark recovery after photobleaching. Oguchi disease was first described in 1907 and is
characterized by golden-brown discoloration of the fundus of retina upon light adaptation
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that disappears after prolonged dark adaptation (Mizuo-Nakamura phenomenon). Oguchi
causing mutations in GRK1 have been reported in patients of European ancestry [84]. All
these patients suffer abnormal recovery kinetics of rod cells. One case involves
heterozygous mutations in the two alleles bearing a point mutation V380D in exon 5
(residue in the catalytic domain) of one allele and a frameshift mutation Ser-536 (4-bp
del) in exon 7 of the second allele that results in premature termination of the protein.
The unaffected family members of the patient were found to be carriers of one of the two
mutations and were normal. Another patient was found to be homozygous for deletion of
residues 357-398 (within the catalytic domain) in the exon 5. In addition, a frameshift
mutation was predicted that would result in premature termination 18 codons downstream
resulting in a non-functional kinase. A variant form of Oguchi disease was recently found
in a Pakistani family encompassing a deletion of exon 3 resulting in a non-functional
protein [85]. The recently reported missense mutation P391H in two Japanese siblings in
a consanguineous family with reduced cone cell responses [86] suggests a role of GRK1
in recovery of cone photoreceptors as well.
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Project Goals
 The crystal structures of GRK2 (PDB code: 1OMW) [60] and GRK6 (PDB code: 2ACX)
[63] defined the structures of two sub-families of GRKs. These structures resolved the
common domain organization of GRKs and enabled us to predict the orientation of GRKs
at the membrane surface.  However, it is still not well established as to how GRKs
recognize activated GPCRs and how this interaction in turn activates the kinase. These
questions remain unanswered in part because critical structural elements were disordered
in all the prior structures of GRKs. This includes the extreme amino terminus and the
kinase C-terminal extension of GRKs. The aim of this project was to crystallize bovine
GRK1. This would be the first structure of the vertebrate-specific subfamily of GRKs. In
addition, relatively higher affinity of GRK1 (2-4 µM) for ATP compared to GRK2 and
GRK6 (~35 µM) makes GRK1 an ideal system for studying nucleotide-ligand complexes
[87].
Structural Analysis of GRK1
The structural analysis of GRK1 has been hindered owing to the poor yields and the
apparent instability of the purified protein. The first step to determine the atomic structure
of GRK1 was thus the purification of sufficient amounts of homogenous and catalytically
active GRK1. We designed a soluble variant of GRK1 lacking the C-terminal 26 residues
for expression in insect cells. The next step was finding the conditions under which
GRK1 crystallized followed by collection of X-ray diffraction data and structural
analysis.
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Functional Analysis of GRK1
 The N-terminus of GRK1 was revealed in one of the Mg2+·ATP·GRK1 structures and
mass spectral analysis provided evidence of phosphorylation at two previously
unidentified sites (Ser5 and Thr8).  In addition, the RH domain mediates dimerization in
all the crystal forms of GRK1, similar to that observed for GRK6. The functional roles of
the phosphorylation sites and the residues at the dimer interface was assessed using
steady-state kinetics of site-directed mutants.
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METHODS
Generation of pFastBac Dual-His6 Vector
The pFastBac Dual vector (Invitrogen) was re-engineered to introduce a
hexahistidine tag followed by a stop codon after the SalI site (downstream of the
polyhedrin promoter, PH). Two oligonucleotides (SalIH6stop and revSalIH6stop)
containing the hexahistidine sequence and a stop codon were designed such that the ends
were complementary to the overhangs generated in the pFastBac Dual vector after SalI
and SpeI digestion (Table 1).
The 5′ end of the oligos was phosphorylated using T4 polynucleotide kinase
(Promega) followed by incubation of their equimolar mixture at 95 °C for 5 minutes. To
facilitate annealing of oligos, the mixture was then gradually cooled to room temperature.
The hybridized oligos were ligated into the SalI/SpeI sites of pFastBac Dual vector. The
ligation mixture was transformed into DH5α cells and an ampicillin-resistant (100 µg/ml)
positive clone was confirmed by DNA sequencing (DNA core facility, ICMB, University
of Texas at Austin). The modified vector will be henceforth referred to as the pFastBac
Dual-His6 vector (Fig. 5) and lacks the SstI site.
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Figure 5. Schematic representation of pFastBac Dual-His6 vector.
pFastBac Dual vector (Invitrogen) was re-engineered to replace the SstI site at the PH promoter
with a hexahistidine tag followed by a stop codon (shown in red). The unique restriction sites
have been labeled and the arrows (black) indicate the directionality of the multiple cloning sites
downstream of the respective promoters. The graphic map was created using PlasMapper
(http://wishart.biology.ualberta.ca/PlasMapper/).
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Cloning of Bovine GRK1535 into pFastBac Dual-His6 Vector
A soluble variant of bovine GRK1 (residues 1-535, GRK1535) was amplified from
GRK1 cDNA in pRK5 vector (a gift from Dr. Robert Lefkowitz, Howard Hughes
Medical Center, Duke University, North Carolina) using Pfu Polymerase (Stratagene).
The PCR amplification was carried out using Grk1fBamHI and rGrk1short535 primers
(Table 1) with an annealing temperature of 63 °C.
The GRK1535 PCR fragment was ligated into the BamHI/SalI sites of pFastBac
Dual-His6 vector, downstream of the polyhedrin promoter. The ligation reaction was
transformed into DH5α cells, ampicillin-resistant (100 µg/ml) transformants were picked
and a positive clone was confirmed by DNA sequencing (DNA core facility, ICMB,
University of Texas at Austin). Recombinant protein expressed using this vector
construct will contain exogenous valine and aspartate residues (from SalI restriction site)
followed by a non-cleavable hexahistidine tag at the C-terminus (Fig. 6).
Cloning of Bovine GRK1 and Mutants into a pcDNA3.1 Vector
PCR fragment encoding wild-type bovine GRK1 was amplified from the GRK1
cDNA vector in pRK5 (a gift from Dr. R. Lefkowitz) using Grk1fBamHI and Grk1rXhoI
primers (Table 1). 30 cycles of amplification with the annealing temperature 59 °C were
carried out using Pfu Turbo polymerase (Stratagene). The PCR fragment was then ligated
into the BamHI/XhoI sites of the pcDNA3 vector (Fig. 7). Ligation mixture was
transformed into DH5α cells and transformants were selected based on resistance to
ampicillin (100 µg/ml). Plasmid DNA was purified and positive clones were confirmed
by DNA sequencing (DNA sequencing facility, University of Michigan). The pcDNA3-
GRK1 vector was used as a template to generate dimer-interface mutants (D164A,
L166K, W531A, D164A/L166K, D164A/W531A, L166K/W531A) and amino-terminal
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mutants (T8A, T8E, T8D, S5A, S5D) using the QuikChange Mutagenesis Kit
(Stratagene). Refer Table 2 for the list of GRK1 mutagenesis primers.
Cloning of Bovine GRK1 and Mutants into pFastBac HTB Vector
 GRK1 in pcDNA3.1 vector was sub-cloned into the pFastBac HTB vector for
expression in High Five cells. The fragment encoding bovine GRK1 or a mutant in
pcDNA3.1 was excised with BamHI and XhoI enzymes and ligated into pFastBac HTB
vector downstream of polyhedrin promoter (Fig. 8). Ampicillin-resistant clones (100
µg/ml) were picked and DNA sequence was verified (DNA sequencing facility,
University of Michigan, Ann Arbor). The fusion protein expressed bears a TEV cleavable
His6 sequence at the N-terminus. Digestion with TEV protease results in five exogenous
residues at the N-terminus (gly-ala-met-gly-ser) of GRK1.
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Figure 6: GRK1535 construct cloned into pFastBac Dual-His6 vector.
A PCR fragment encoding residues 1-535 of bovine GRK1 was cloned at the BamHI/SalI sites
(blue and italicized) downstream of the Polyhedrin (PH) promoter. The vector sequence is in
lower case. The numbers (top panel) indicate the start of the restriction site sequence. The 6 x His
tag and the stop codon (underlined) in the vector sequence are colored red.
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Table 1. List of primers used for cloning.
Restriction enzymes sites are underlined and the stop codon is in bold text and italicized.
The glycine to alanine mutation (to prevent myristoylation) at position 2 in Gαi1 sequence
is in red in the primer sequence.
Name Sequence Restrictionenzyme site
SalIH6stop 5'-TCGACCACCATCACCATCACCATTAAA-3' Sal I
revSalIH6stop 5'-CTAGTTTAATGGTGATGGTGATGGTGG-3' Spe I
Grk1fBamHI 5'-GTAGTAGGATCCATGGATTTCGGGTCCCTGGAGA-3' BamH I
Grk1rXhoI 5'-CAAGTACTCGAGTTACTAGGAAAGCACACACATGC-3' Xho I
rGrk1short535 5'-CAAGTAGTCGACCCCGTCGGGCCGCCACACG-3' Sal I
Gbeta1for 5'-GTAGTAGTCGACATGAGTGAACTTGACCAGTTACGGC-3' Sal I
revGbeta1 5'-CAAGTAAAGCTTTTAGTTCCAGATTTTGAGGAAGCTGT-3' Hind III
mutGi1forXmaI 5'-GTAGTACCCGGGATGGCCTGCACACTGAGCGCTGAGG-3' Xma I
rev28Gi1BglII 5'-CAAGTAAGATCTCTCTCCGTCCTCCCGGAGGTTA-3' Bgl II
G16for40BglII 5'-GTAGTAAGATCTCGCGGGGAGCTGAAGCTGCTGCTTT-3' Bgl II
revG16KpnI 5'-CAAGTAGGTACCTCACAGCAGGTTGATCTCGTCCA-3' Kpn I
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Table 2. GRK1 mutagenesis primers.
The mutations in the primer sequences are in red.
Mutant Primer Sequence Template
(in pcDNA3)
Grk1D164Af 5’ -CTTCCAGGAGTTCCTGGCCAGCCTCTACTTCCTGC- 3’
D164A
Grk1D164Ar 5' - GCAGGAAGTAGAGGCTGGCCAGGAACTCCTGGAAG - 3'
GRK1
mL166Kf 5' - CCAGGAGTTCCTGGACAGCAAGTACTTC - 3'
L166K
mL166Kr 5' - GAAGTACTTGCTGTCCAGGAACTCCTGG - 3'
GRK1
mW531Af 5' - ACTTGAACGTGGCGCGGCCCGACGGGCAGAT - 3'
W531A
mW531Ar 5' - ATCTGCCCGTCGGGCCGCGCCACGTTCAAGT - 3
GRK1
mDLf 5' - CCAGGAGTTCCTGGCCAGCAAGTACTTC - 3'
D164A/L166K
mDLr 5' - GAAGTACTTGCTGGCCAGGAACTCCTGG - 3'
GRK1
mW531Af 5' - ACTTGAACGTGGCGCGGCCCGACGGGCAGA  - 3'
D164A/W531A
mW531Ar 5' - ATCTGCCCGTCGGGCCGCGCCACGTTCAAGT - 3
GRK1
D164A
mW531Af 5' - ACTTGAACGTGGCGCGGCCCGACGGGCAGAT - 3'
L166K/W531A
mW531Ar 5' - ATCTGCCCGTCGGGCCGCGCCACGTTCAAGT - 3
GRK1
L166K
TPO8f 5' - GATTTCGGGTCCCTGGAGGCGGTGGTGGCCAATTCAGCC - 3'
T8A
TPO8r 5' - GGCTGAATTGGCCACCACCGCCTCCAGGGACCCGAAATC - 3'
GRK1
TPO8Ef 5' - GATTTCGGGTCCCTGGAGGAGGTGGTGGCCAATTCAGCC - 3'
T8E





















Figure 7: Schematic representation of GRK1 and mutants cloned into pcDNA3.1
vector.
Bovine GRK1 gene was cloned at BamH I/Xho I sites (in blue) downstream of T7
promoter. The numbers (bottom panel) indicate the start of the restriction sequence.
Vector sequence is in lower case. The vector encodes resistance to ampicillin and
neomycin (NTP_II marker).
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Figure 8. GRK1 and mutants cloned into pFastBac HTB expression vector.
Fragment encoding bovine GRK1 and mutants was excised from the pcDNA3.1 construct
and sub-cloned into the BamHI/Xho I sites (in blue) of pFastBac HTB vector. The vector
sequence is in lower case.
- 30 -
Generation of Recombinant Baculoviruses
Recombinant baculoviruses were generated using the Bac-to-Bac Baculovirus
Expression System (Invitrogen). A range of 1-5 ng of pFastBac construct (GRK1535-His6
or GRK1 or a mutant) was used for transformation of 10 µl MAX Efficiency DH10Bac
(Invitrogen) chemically competent E. coli cells (instead of 5 pg per 100 µl cells) as this
yielded a reasonable number of colonies for blue/white colony screening. The cells were
incubated on ice for 30 minutes and then heat-shocked for 45 seconds at 42 ºC. The tubes
were chilled on ice for about two minutes before adding 90 µl of room temperature
S.O.C. medium (Invitrogen). The cells were then transferred to a 14 ml polypropylene
round-bottom tube (Becton Dickinson) and incubated in a shaker at 37 ºC for four hours
(225 rpm) to allow cells to recover from heat-shock. During this incubation site-specific
transposition occurs thus incorporating the expression cassette into the bacmid DNA.
Next, 100 µl of a 1:10 and 1:20 dilution of cells in the S.O.C. medium was plated on
TKG plates, [Luria-Bertini (Miller’s) broth (ISC Bioexpress) agar plates containing 50
µg/ml kanamycin, 10 µg/ml tetracycline, 7 µg/ml gentamicin, 40 µg/ml IPTG and 100
µg/ml X-gal (was added fresh)]. The plates were incubated for 48 hours at 37 °C. A few
large and isolated white colonies were picked and restreaked on fresh TKG plates. A
clone that had a white phenotype on restreaked plate and no longer grew on LB plates
(100 µg/ml ampicillin) was used to inoculate a 5 ml overnight culture containing 50
µg/ml kanamycin, 10 µg/ml tetracycline and 7 µg/ml gentamicin. A glycerol stock of
bacmid was stored at –80 °C. Recombinant bacmid DNA was prepared fresh by the
ethanol precipitation method (protocol from Bac-to-Bac Baculovirus expression system
user manual). Wide-bore pipette tips were used to avoid shearing of the large bacmid
DNA. Purified bacmid DNA in 1X TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA)
was used to transfect High Five insect cells using cationic transfection agent FuGENE 6
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(Roche). Approximately 2 x 106 High Five cells grown in Insect Xpress medium
(Cambrex) supplemented with 100 units/ml penicillin (Gibco) and 100 µg/ml
streptomycin (Gibco) were plated in a T-25 flask (Corning) in a total volume of 5 ml.
Cells were allowed to attach to the surface for one hour at 28 ºC. In a sterile 1.5 ml
eppendorf tube, 3 µl FuGENE6 was mixed with 97 µl of room temperature Dulbecco’s
modified Eagle’s medium (DMEM, Gibco), which does not contain serum or antibiotics.
The tube was flicked to mix the contents and incubated at room temperature for 5
minutes. Approximately 2 µg bacmid DNA (in TE buffer, pH 8.0) was added to the
diluted FuGENE6 and mixed by tapping the tube. The DNA:lipid mixture was incubated
at room temperature for 15-30 minutes and then added to the cells. The flask was swirled
to mix and incubated in 28 ºC humidified incubator for 3-5 days.
Clarified supernatant containing the virus was harvested by centrifugation (3000
X g for 5 minutes) and labeled the “P1 virus”. Virus was stored at 4 °C in the dark and an
aliquot was also kept at –80 °C for long-term storage. To generate a high-titer virus, 100
ml culture of High Five cells at a density close to 2 x 106 cells/ml in a 1 L baffled flask
was infected with 100 µl of P1 virus. The cell culture was incubated in a shaker (140 rpm)
at 28 °C. Cells were harvested 72-96 hours post viral addition when >90% cells were
lysed. Virus thus amplified was labeled “P2”. “P3” virus made by infecting 250 ml cells (2
x 106 cells/ml) with 300 µl of P2 virus was used for infecting six liters of High Five cells
for protein expression.
Expression and Purification of Recombinant GRK1535-His6
For protein expression, six liters (8 x 750 ml in 2 L baffled flasks) of High Five
cells were grown in Insect Xpress medium containing 100 units/ml penicillin and 100
µg/ml streptomycin in a 28 ºC shaker at 140 rpm. When the cell density was close to 2 x
106 cells/ml, 30 ml of “P3 virus” was added per 750 ml cell culture. Approximately 40
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hours post viral addition cells were harvested by centrifugation at 1500 X g for 15
minutes in Beckman JLA 8.100 rotor. The pellet was flash-frozen in liquid nitrogen and
stored at –80 °C.
Thawed High Five cell pellet was resuspended in approximately 100-150 ml of
cold lysis buffer (Buffer A) containing 20 mM Na-HEPES pH 7.5, 300 mM NaCl, 10
mM β-mercaptoethanol and fresh EDTA-free protease inhibitor cocktail (Roche). When
using the dounce homogenizer (40 ml capacity, Wheaton) cells were lysed with 10 passes
of loose pestle followed by 10 passes of tight pestle. An additional step was 40 pulses
(one second each) of a sonicator (VirSonic 60, VirTis). Alternatively, cells were lysed by
one or two passes through Emulsiflex-C3 (Avestin) high pressure homogenizer at 10,000
psi. Samples were checked for lysis under a light microscope and then spun at 40,000
rpm for 45 minutes (4 °C) in a Beckman Ti-45 rotor. The supernatant was filtered using a
combination of 1.2 µ filter (Millipore) and a glass filter (Fisherbrand) and diluted to a
final protein concentration of 5 mg/ml with Buffer A. All the purification steps were
carried out at 4 °C. The diluted supernatant was loaded onto a 5 ml Ni2+-NTA drip
column (Qiagen) pre-equilibrated with Buffer A. After washing with 10 column volumes
(CVs) of Buffer A and 20 CVs of Buffer B (Buffer A containing 20 mM imidazole pH
8.0) the bound protein was eluted in 2-3 ml fractions with Buffer C (Buffer A with 150
mM imidazole pH 8.0). (Fig. 9A) The low imidazole wash (Buffer B) elutes appreciable
amount of GRK1535-His6, and using a 10 ml Ni2+-NTA column solved the problem.
Fractions containing GRK1535-His6 (in Buffer C) were pooled and diluted six-fold
with a buffer containing 20 mM Na-HEPES pH 7.5 and 1 mM DTT to lower the final
ionic strength of the solution to ≤50 mM NaCl. Diluted and filtered GRK1535-His6 was
loaded onto an 8 ml Source 15S column (Pharmacia) pre-equilibrated with ion exchange
buffer A (20 mM Na-HEPES, 50 mM NaCl and 1 mM DTT) at a flow rate of 2 ml/min.
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Protein was eluted in an 80 ml gradient of 0-40% ion exchange Buffer B (20 mM Na-
HEPES pH 7.5, 1M NaCl and 1 mM DTT). GRK1535-His6 elutes in five peaks. A better
separation of different peak fractions was observed using a shallow gradient of 0-30%
Buffer B (80 ml). The Source 15S fractions (0.6 ml each) were pooled and labeled as:
Pool A (peak 1), Pool B (peaks 2-3) and Pool C (peak 4)
(Fig. 9B). A fifth peak (Pool D), which elutes in high salt wash (1M NaCl) appears to
contain aggregated protein as it clogs the filter when the pooled fractions are
concentrated. This peak fraction was discarded. The Pool A fractions elute at NaCl
concentration ranging from 140 to 175 mM, Pool B elutes at 180-210 mM NaCl whereas
Pool C elutes at an approximate NaCl concentration of 220 mM. The various pooled peak
samples were concentrated to 10-15 mg/ml using a 50 kDa molecular weight cutoff
centriprep (Millipore), and flash-frozen as 50 µl pellets in liquid nitrogen. Protein at this
stage was ~95% pure (estimated by SDS-PAGE) and hence not purified further. Yield of
pure GRK1535-His6 (Pool A) varies from 7-10 mg/L of cell culture.
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Figure 9: Purification of recombinant GRK1535-His6.
A. Ni2+-NTA affinity purification. The hexahistidine tag at the C-terminus of
GRK1535-His6 enables affinity purification on a Ni2+-NTA column. Samples have
been labeled, from left to right: (M) protein standards, (1) pellet fraction after cell
lysis, (2) supernatant fraction containing soluble protein after ultracentrifugation
run, (3) flow-through of supernatant loaded onto the Ni2+-NTA column, (4)
column wash with Buffer A, (5) column wash with Buffer B, and (6)-(19) protein
eluted with Buffer C.  The fractions containing GRK1535-His6 (lanes labeled 6-18)
were pooled and further purified on a cation exchange column.
B. SDS-PAGE and chromatogram of elution from Source 15S column. Samples
have been labeled (from left to right), (M) protein standards, (L) diluted GRK1535-
His6 (from nickel affinity purification step) loaded onto Source 15S column.  The
fractions eluted with an increasing NaCl gradient have been pooled as:  fractions
14C-2C (peak 1) were pooled as Pool A, fractions 1B-8B (peaks 2-3) as Pool B,
fractions 10B-14B (peak 3) were pooled as Pool C. Fraction 8B represents the
peak fraction of Pool D (fractions 5B-12B). The fractions pooled as Pool A, B, C
and D have been marked on the gels and the chromatograms in four different
colors. (FT) is the flow-through of protein loaded on the column.
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Expression of GRK1 and Mutants in COS-1 Cells
COS-1 cells grown to about 50% confluency in 100 mm dishes were transiently
transfected with either wild-type bovine GRK1-pcDNA3 or a mutant in vector.
Transfection was carried out based on manufacturer’s protocol (Roche) using 18 µl of
FuGENE 6 (Roche) and 6 µg plasmid DNA (a ratio of 3:1). Cells were harvested
approximately 44 hours post transfection. Cell pellets were partially purified using SP-
Sepharose FF resin (Pharmacia) as described earlier [88]. GRK1 was eluted with 300 mM
NaCl. The eluate was analyzed (10 µ l) by immunoblotting using either an antibody
directed against residues 17-34 of GRK1 (rabbit GS-19 or GS-20, a gift from Dr. K.
Palczewski) or an antibody that recognizes the C-terminal 20 residues of GRK1 (rabbit
polyclonal C-20, Santa Cruz). The empty pcDNA3.1 vector was processed in a similar
manner. The yield of purified protein was too little and not homogenous, which would
not allow us to assess the mutants using steady state kinetics. Hence, GRK1 and mutants
were expressed in baculovirus infected Five cells.
Expression and Purification of His6-GRK1 and Mutants in High Five Cells
GRK1 and mutants were expressed in High Five cells similarly to the expression
of GRK1535-His6. Following lysis and ultracentrifugation run the pellet fraction
(containing membrane-bound protein) was resuspended in the lysis buffer containing 300
mM NaCl and slowly poured in liquid nitrogen. Popcorn-like residues formed were
stored at –80 ºC. The soluble fraction of the protein was purified on a 5 ml Ni2+-NTA
column as described for GRK1535-His6 (Fig. 10A). Fractions containing His6-GRK1
fusion protein (calculated mass is ~66.3 kDa) were pooled and dialyzed overnight at 4º C
against a buffer containing 20 mM Na-HEPES pH 7.5, 300 mM NaCl and 10 mM β-
mercaptoethanol in the presence of 2-3 % (w/w) TEV protease. Digestion with TEV
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protease cleaves the His6 tag, and as a result of which GRK1 does not bind to a Ni2+-NTA
column and thus can be purified from the uncut His6-tagged fusion protein. The final
purification step was cation exchange chromatography on a 8 ml Source 15S column
(Pharmacia) and was carried out similarly to the GRK1535-His6 purification (Fig. 10B).
The purification of membrane-bound His6-GRK1 (the fraction of protein that is
expected to be farnesylated at the C-terminus) was carried out the following day. Thawed
membrane resuspension was solubilized in 1% (v/v) Triton X-100 (Amresco) and stirred
on ice-bath for an hour. The solubilized protein was separated from cell debris by
ultracentrifugation and purified similarly to the method used for the purification of
soluble fraction with the only difference that all the buffers used were supplemented with
0.02% (w/v) dodecyl maltoside, DDM (Dojindo). The soluble and membrane-bound
proteins also were purified as a mixture from homogenized cells in the presence of 0.02%
DDM.
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Figure 10. Purification of wild-type GRK1.
The purification profile of soluble fraction of GRK1 wild-type protein is shown here, The
purification of GRK1 and mutants and the membrane fraction of each protein differs at the
Source S purification step, where the elution of protein is observed in multiple peaks. The number
of peaks and the ionic strength at which they elute varies slightly.
A. Ni2+-NTA affinity purification. GRK1 and mutants are expressed as His-tagged
proteins, which can be cleaved by TEV protease. The samples have been labeled from
left to right as; (M) protein standards, (1) pellet fraction after lysis and
ultracentrifugation, (2) supernatant fraction after ultracentrifugation containing soluble
fraction of protein, (3) Flow-through of loading protein on nickel column, (4) wash with
the lysis buffer, (5) wash with buffer B containing 20 mM  imidazole, (6) GRK1
containing fractions eluted from nickel column were pooled based on Bradford analysis
and, (7) GRK1 containing pooled fractions (in lane labeled 6) were dialyzed overnight in
the presence of 3 % w/w TEV protease.
B.  Purification on Source S column. After overnight dialysis in the presence of TEV
protease, GRK1 was purified on a second Ni2+-NTA column to separate it from the uncut-
fusion protein. The dialyzed protein was loaded on nickel column and the flow-through
that contains the cut protein was collected. The flow-through was diluted five times to
lower the ionic strength and purified on a Source 15S column. The samples have been
labeled from left to right as; (M) protein standards and, (3C) – (3A) fractions eluted with
a salt gradient. Protein at this stage elutes in multiple peaks (upto four/five) and the peak
fractions containing pure GRK1 (Peak 2) that were pooled have been marked on the gel.
The first peak usually contains fusion protein or a mixture of fusion and TEV-cleaved
protein and these fractions were not pooled.
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Western Blot Analysis of GRK1535-His6
GRK1535-His6 samples (10, 30 and 100 ng) or GRK1 and mutants (10 µl each)
expressed in COS-1 cells were separated by 10% SDS-PAGE. A prestained kaleidoscope
marker (Bio-Rad) was loaded in one well to help assess the extent of transfer. A PVDF
membrane (Millipore) was prepared by submerging it in the transfer buffer (20%
methanol, 48 mM Tris base, 39 mM glycine and 1.3 mM SDS) for about 1-2 minutes. The
left-hand corner of the membrane was trimmed to help orient the membrane. Two
blotting pads (VWR) were prepared by soaking them in 20% methanol. The assembly
process was carried out in the following order: a wet blotting pad was laid down first on
the anode plate followed by a wet PVDF membrane, protein gel and then the second wet
blotting pad was placed on top. A small glass tube was rolled over to remove all the air
bubbles before assembling the cathode plate. Transfer was carried out at 10 V for an hour
on a semi-dry transfer cell (Bio-Rad).
The membrane after transfer was blocked using 5% milk in 1X PBS for 30
minutes at room temperature. The blot was probed with a 1:1000 dilution (in blocking
buffer) of a rabbit GS-19 or GS-20 antibody, which recognizes residues 17-34 of GRK1
(gifts from Dr. K. Palczewski, Case Western Reserve University, Cleveland, Ohio) or a
C-terminal antibody, C-20 from Santa Cruz. The incubation with the primary antibody
was carried out for an hour either at room temperature or overnight at 4 ºC. The
secondary antibody was HRP goat anti-rabbit IgG (H+L) (Zymed) used at 1:3000
dilution in blocking buffer for an hour at room temperature. The blot was washed thrice
(for five minutes each), both after the transfer and after incubation with the two
antibodies. To determine if the C-terminus of GRK1535-His6 was intact, Penta-His HRP
conjugate (Qiagen) was used as per manufacturer’s instructions. In either case, the blot
was developed using the LumiGLO chemiluminescent substrate system (KPL) and then
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scanned with a Typhoon 9410 Imager (Amersham). The bands were quantified using
ImageQuant software version 5.2 (Molecular Dynamics).
Incubation With ATP
To assess if the different pooled peaks of GRK1535-His6 (Source 15S purification
step) correspond to different phosphorylation forms or if they were the truncated protein
products, Pool A and C samples of GRK1535-His6 were incubated with a final
concentration of 4 mM  ATP pH 7.5 and 2 mM  MgCl2, both at 4 ºC (to mimic
crystallization conditions) and room temperature. An aliquot of protein sample was taken
after two hours and overnight incubation. SDS-PAGE was carried out at a low voltage
(~50 V) under ice-cold conditions. The gel was either stained with Bio-safe Coomasie
(Bio-Rad) or analyzed by western blotting.
Recoverin Binding Assay
Nonacylated-recoverin (NA-recoverin) was coupled to CNBR-activated
Sepharose CL-4B beads [30]. Approximately 50 µg GRK1535-His6 from Pool A, B and C
were incubated with 30 µl recoverin resin (in binding buffer containing 20 mM  Na-
HEPES pH 7.5, 100 mM NaCl, 2 mM MgCl2, 1 mM CaCl2, 1 mM DTT and 200 µM
PMSF) for an hour at 4 °C. The unbound protein was collected by centrifugation and the
resin was washed twice with binding buffer containing 500 mM NaCl. Bound-GRK1 was
eluted with a buffer (binding buffer without 1 mM CaCl2) containing 5 mM EGTA and
analyzed by SDS-PAGE or immunoblotting.
N-terminal Sequencing of GRK1535-His6
The N-terminal amino acid sequence analysis was accomplished by Edman
degradation using a protein sequencer from Applied Biosystems Model 494HT (Applied
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Biosystems, Foster City, CA, USA) at University of Michigan Protein Structure Facility,
Ann Arbor. The protein was blotted onto a PVDF membrane (Millipore) and stained with
Biosafe Coomasie (Bio-Rad). The protein bands were excised and washed three times
with water after wetting with methanol. The PVDF bands were air dried and placed into
the sequencer cartridge (Applied Biosystems). Sequence analysis was performed using
the manufacturer’s method for proteins in gas phase mode. Detection of PTH
(Phenylthiohydantoin)-amino acids was at 269 nm by an Applied Biosystems 140C LC-
system. Data analysis was performed using the Applied Biosystems Model 610A data
analysis softwareTM (Version 2.1). Amino acids were assigned in comparison to a
standard mixture containing 19 PTH-amino acids as supplied by the instrument
manufacturer.
Phosphoaminoacid Analysis
Dr. Benlian Wang (Center for Proteomics and Mass Spectrometry, Case Western
Reserve University) conducted these experiments. GRK1535-His6 (20 µg) in 20 µl of 1 M
pH 8.0 Tris-HCl buffer consisting of 8 M Urea was reduced by dithiothreitol (DTT) for 2
hrs at 30 ºC.  An S-alkylation treatment was then done by adjusting the solution to 2.5
mM idoacetamide and reacting for 30 min at 25 ºC in dark. After about 10- fold dilution
with water, sequencing grade modified trypsin (Promega, Madison, WI) was added at an
enzyme to protein ratio of 1:50 (w/w). The digestion was carried out for 16 hrs at 37 ºC.
In case of endogenous rhodopsin kinase (a gift from Dr. K. Palczewski, Case Western
Reserve University, Ohio), digestion was performed in the gel. The band containing RK
was first excised from the SDS-PAGE gel and then destained with 50% acetonitrile in
100 mM ammonium bicarbonate, and 100% acetonitrile. The protein was reduced and
alkylated using 20 mM DTT and 50 mM idoacetamide respectively, for 30 minutes each
in dark. The reaction reagents were removed and the gel pieces were washed with 100
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mM  ammonium bicarbonate, dehydrated in acetonitrile. The dried gel pieces were
reswelled in 50 mM  ammonium bicarbonate containing sequencing grade modified
trypsin for overnight digestion. Tryptic peptides were extracted from the gel with 50%
acetonitrile in 5% formic acid.
MonoTip TiO (GL Sciences Inc, Tokyo, Japan) was used to enrich
phosphopeptides according to the manufacture’s protocol. The Tip was first conditioned
with 100% acetonitrile, 0.2 M phosphate buffer (pH 7.0) and equilibrated with 50%
acetonitrile in 0.1% formic acid. Samples were loaded and rinsed with 30% acetonitrile in
0.1% formic acid and 0.1 M potassium chloride. Phosphopeptides were eluted from the
column with 2.5% aqueous ammonia in 20% acetonitrile and concentrated by vacuum
centrifuge followed by resuspension in 0.1% formic acid. LC-MS/MS analysis of the
tryptic digests were performed using a quadrupole ion trap mass spectrometer (model
LTQ) from Thermo-Finnigan (San Jose, CA) coupled with an Ettan MDLC system (GE
Healthcare, Piscataway, NJ). Phosphopeptides were acquired in positive ion mode, and
automatic data-dependent neutral loss scan method. That is, when a specific neutral loss
(-49 Da and -32.7 Da for the doubly and triply charged ions) on fragment ions (MS2) was
detected, MS3 was automatically triggered. The obtained data were submitted to
Bioworks by searching the phosphorylation on serine, threonine and tyrosine residues.
The sites of phosphorylation were confirmed by tandem MS2 and/or MS3.
Intact mass Analysis
GRK1535-His6 samples were desalted using Vydac C4 ultramicrospin column (The
Nest Group) according to the manufacturer’s protocol and then reconstituted in a solution
containing 50% acetonitrile-0.1% formic acid. The samples were infused to QSTAR XL
mass spectrometer (Applied Biosystems) through a syringe pump at 0.5 µl/min. The
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intact protein mass was analyzed by Bayesian protein Reconstruct using Analyst QS 1.1
software.
Rhodopsin Phosphorylation Assays
Urea-stripped bovine rod outer segments (uROS) used in the assays were either a
gift from Dr. Rachel Sterne-Marr, Siena College or were prepared in the laboratory
following the method described elsewhere [52] . Rhodopsin phosphorylation assays were
carried out following the protocol described earlier [88]. Briefly, an assay mixture was
prepared containing 2.5 µM uROS, 20 mM Tris-HCl pH 7.5, 2 mM EDTA, 5 mM MgCl2,
0.1 mM ATP pH 7.5 and ~10 µCi [γ-32P]ATP (MP Biomedicals). The assay mixture tube
was covered with aluminium foil to protect it from light. Reaction was initiated by adding
1 µl of GRK1535-His6 (from Source 15S purification step) per 9 µl assay mixture followed
by exposing the samples to room light at 30 ºC.
Concentration dependent assay
The amount of GRK1535-His6 protein (Pool A, B and C) used in a 10 µl reaction
was 10 ng (16.3 nM), 30 ng (50 nM) or 100 ng (166.7 nM). Reaction was quenched after
10 minutes by addition of 10 µl of 2X SDS-loading buffer. Half of the sample was loaded
on a SDS-PAGE gel and the gel was run until the dye front ran out of the gel (contains
unincorporated [γ32-P]ATP). The gel was dried and exposed to a phosphorimager screen.
The screen was scanned after overnight exposure using a Typhoon 9410 Imager
(Amersham) and the ImageQuant software version 5.2 (Molecular Dynamics) was used
to analyze the data. For a control, 10 ng bovine GRK2 was used.
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Time course experiment
Pool A and C samples of GRK1535-His6 (30 ng or 50 nM each) were used to assay
the time course of rhodopsin phosphorylation in uROS. Reactions were terminated by
addition of 10 µl of 2X SDS-loading buffer 1, 3, 5, 7.5, 15, 20, 30 and 40 minutes after
the addition of kinase.
Rhodopsin: Km and Vmax measurements
To monitor the time course of rhodopsin phosphorylation, a 100 µl assay mixture
was prepared containing 20 µM ROS, 2 mM MgCl2, 20 mM Bis-tris propane, pH 7.5, 40
nM soluble fraction of GRK1, and 100 µM  [γ-33P]ATP mix (100-1000 cpm/pmol, Perkin
Elmer). Reactions were initiated by illuminating the samples at 30 °C. Reactions were
quenched after 0, 1, 2.5, 5, 7.5, 10, 15 and 20 minutes by addition of 1 ml of 10%
trichloroacetic acid, TCA (Sigma). The assay was carried out with each measurement in
duplicate. Samples were pelleted by centrifugation at maximum speed for 2 minutes and
the supernatant containing unincorporated 33P was discarded. The pellet was washed 3-4
times with 1 ml of 10% TCA until the counts in the washes were <500. After extensive
washing, the pellet was dissolved in 88-97% formic acid and mixed with 5 ml
scintillation fluid (Opti-Fluor, Packard Bioscience). The radioactivity was measured
using a scintillation counter.
For kinase titrations, a 100 µl assay mixture was prepared the same way except
that the amount of kinase was varied from 0-245 ng (0-39 nM) of soluble fraction of
GRK1 and 0-125 ng (0-20 nM) of membrane fraction or mixture of both. The reactions
were initiated by addition of 100 µM  [γ−33P  ] ATP mix (100-1000 cpm/pmol) and
illumination at 30 °C. Reactions were quenched after 10 minutes (based on the time
course assays) by addition of 1 ml of 10 % TCA. Samples were processed and analyzed
similarly to the time course experiment.
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For Km and Vmax measurements, assay mixtures (100 µl) were prepared as
described above containing either 8 nM membrane fraction or 18 nM soluble fraction of
GRK1 (concentrations used were based on kinase titrations). The amount of uROS was
varied from 1-40 µM. Reactions were initiated by addition of 0.1 mM [γ-32P]ATP mix
(100-1000 cpm/pmol, Amersham) and illumination at 30 °C. Two measurements were
made for each concentration of uROS in 2-3 independent assays. Reactions were
quenched and processed as described above. Similar assays for GRK1535-His6 were
carried out using 18 nM Pool A and B (10 min) and 65 nM Pool C (20 min). Protein
amounts were normalized by SDS-PAGE and A280 measurements (>95% homogenous).
The data were analyzed by non-linear analyses and curve-fitting programs of GraphPad
Prism version 4.0a for Macintosh. The kinase activity was expressed as nanomoles of 33P
or 32P incorporated per minute per milligram of kinase. The linearity of the reaction was
confirmed using the double-reciprocal plot.
Size Exclusion Chromatography
GRK1535-His6 (~75 µM) was loaded onto two tandem Superdex 200 HR 10/30
preparative columns (Pharmacia) pre-equilibrated with 20 mM Na-HEPES pH 7.5, 100
mM NaCl and 1 mM DTT at a flow rate of 0.3 ml/min. GRK1535-His6 elutes in one peak
and the molecular weight corresponds to 69,438 Da (calculated mass is 63,348 kDa),
based on the standard curve using proteins of known molecular weight (Bio-Rad).
GRK1535-His6 containing fractions were pooled and concentrated to 2.54 mg/ml in a 50
kDa MWCO centricon (Millipore) and used for sedimentation equilibrium analysis.
Sedimentation Equilibrium
Sedimentation equilibrium analysis was carried out in Beckman Optima XL-1
analytical ultracentrifuge. A six-channel centerpiece was set up as per manufacturer’s
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instructions. GRK1535-His6 (100 µl) at three different concentrations corresponding to an
A280 of 0.3 (4.9 µM), 0.5 (8.1 µM) and 0.7 (11.4 µM) was loaded in the sample chamber
while 120 µl of GRK1535-His6 gel filtration buffer was loaded in the reference chamber of
the centerpiece. The optimal speed for sedimentation equilibrium run was estimated to be
8,000 rpm based on the plot of rpm/ sedimentation coefficient versus molecular weight
[89], assuming that the protein exists as a monomer in solution (calculated molecular
weight of GRK1535-His6 is 61,348 Da). Protein was sedimented to equilibrium in an An-
50Ti rotor at 4° C under vacuum at 7,000, 10,000 and 15,000 rpm. The three rotor speeds
were selected following the instructions in the Beckman manual. A fourth rotor speed
(25,000 rpm) was selected, in case oligomerization occurred in solution. Three
absorbance scans were recorded for each rotor speed at the three protein concentrations
used in order to ascertain that equilibrium had been attained, starting with the lowest
speed first. Data was analyzed using Ultrascan 7.2 software.
Crystallization of GRK1535-His6
GRK1535-His6 Pool A (7-12 mg/ml) was used for crystallization by hanging drop
vapor diffusion method, either at 4 or 20 °C.  Protein solution (0.8-1.0 µl) solution was
mixed with an equal volume of the well solution. Drops set up with nucleotide ligands
contained protein pre-mixed with a final concentration of 2 mM MgCl2 and either 4 mM
ATP, ADP or AMPPNP, pH 7.5 (the concentrations are based on the crystallization
conditions of GRK6).
Three peptides derived from bovine rhodopsin sequence were synthesized at the
Protein Structure Facility, University of Michigan, Ann Arbor. Peptide P1 contains one
phosphorylation site whereas peptide P3 contains three (phosphorylation sites have been
underlined). A third peptide used was labeled L5-6 (loop 5-6, residues 236-249), which
inhibits rhodopsin phosphorylation by about 62±10% without affecting GRK1
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autophosphorylation. It is also not a substrate for GRK1. All the three lyophilized
peptides (~90% pure) were resuspended in a buffer containing 20 mM Na-HEPES pH 7.5
and 100 mM  NaCl. The pH of the final solution was adjusted to ~7.0 with NaOH.
GRK1535-His6 was pre-mixed with either one or a mixture of the peptides (at a final
concentration of 10 mM). The crystals that grew were not dependent on the presence of
peptide(s). However, presence of nucleotide (4 mM ADP or ATP at pH 7.5 and 2 mM
MgCl2) was essential. Another approach was to soak crystals for an hour in a
cryoprotectant containing 10 mM final concentration of peptide(s) (either at 4 or 20 ºC)
before flash-freezing them.
P1: KTETS343QVAPA  [46]
P3: DDEAS334TTVS338KTETS343QVA [76]
L5-6: 236QQQESATTQKAEKE249 [41]
Crystals of GRK1·(Mg2+)2·ATP appeared under two different conditions at 4 °C
(Fig. 11A, B). Well solution consisted of 11% PEG 6000, 200 mM NaCl, 5% glycerol,
100 mM Na-tartarate pH 4.35 (crystal form I), and 12% PEG 3350, 200 mM NaCl, 5%
glycerol, 100 mM Na-citrate, pH 4.3 (crystal form II). These crystals appeared in 1-2
days and grew to a maximum dimension of 0.6 x 0.02 x 0.06 mm in one week as clusters
of rods. Harvesting solution (the respective well solutions with 20 mM Na-HEPES, pH
7.5, 2 mM DTT, 4 mM ATP, pH 7.5, 2 mM MgCl2, and 5% glycerol) was slowly added
(1µl at a time) to the drops containing the crystals and individual rods were removed
using a cryoloop (Hampton Research) or excised with a scalpel/eye knife (Beaver).
Crystals were then transferred to 50 µl cryoprotectant solution (respective harvesting
solutions with 25% glycerol) and were flash-frozen in liquid nitrogen until data
collection. Crystals did not show any sign of damage even though they were harvested
without a step-wise equilibration to the final harvesting condition.
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Apo-GRK1 grew as hexagonal plates (crystal form III) to a dimension of 0.36 x
0.04 x 0.04 mm at 4 °C (Fig. 11C). These crystals took the longest to nucleate (~2
weeks). The well solution contained 11% PEG 3350, 200 mM NaCl, and 100 mM MES,
pH 6.4. Crystals were harvested similarly to the crystal forms I and II and the
cryoprotectant consisted of the well solution with 20 mM Na-HEPES, pH 7.5, 2 mM
DTT, and 25% glycerol.
Crystals of GRK1·(Mg2+)2·ADP were grown under three different conditions
(crystal forms IV-VI). Crystal form IV grew at 20 °C using well solution containing 22%
PEG 6000, 1 M NaCl, 5% glycerol, and 100 mM MES pH 6.25. Rod-shaped crystals
appeared in 1-2 days and grew to maximum dimension of 0.2 x 0.12 x 0.08 mm over the
course of one week (Fig. 11D).  To prevent damage to the crystals, 1 µl harvesting
solution (24% PEG 6000, 1.2 M NaCl, 100 mM MES, pH 6.25, 20 mM Na-HEPES, pH
7.5, 2 mM DTT, 4 mM ADP, pH 7.5, 2 mM MgCl2, and 5% glycerol) was added at a
time to the crystal containing drops. The crystal was then serially transferred through 50
µl drops of cryoprotectant (harvesting solution) containing glycerol at 6.25%, 12.5% and
25% glycerol. The crystal was soaked in the harvesting solution for two hours at 20 °C in
the presence of 10 mM final concentration each of P1 and L5-6 peptides and was flash-
frozen in the cryostream at the synchrotron. Crystal form V grew to maximum dimension
of 0.2 x 0.05 x 0.02 mm over the course of one week at 4 °C using well solution
containing 15% PEG 8000, 900 mM NaCl, 100 mM MES, pH 6.25, and 5% glycerol
(Fig. 11E). The crystals were harvested similarly to the crystal form IV. The
cryoprotectant consisted of 17% PEG 8000, 1.3 M NaCl, 100 mM MES, pH 6.25, 20 mM
Na-HEPES, pH 7.5, 4 mM ADP, pH 7.5, 2 mM MgCl2, 2 mM DTT, 25% glycerol, and
10 mM P1 peptide. The crystals were soaked for one hour at 4 °C in the peptide
containing cryoprotectant before freezing them in liquid nitrogen.  The crystal form VI
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grew as clusters of rod-like plates at 4 °C using the well solution containing 15% PEG
8000, 800 mM NaBr, 100 mM MES, pH 6.25, and 5% glycerol. The crystals grew to
maximum dimensions of 0.32 x 0.28 x 0.04 mm over the course of two weeks (Fig. 11F).
Individual rods were excised using a cryoloop (Hampton Research) or a scalpel/eye knife
(Beaver) and were harvested in a cryoprotectant solution containing 20 mM Na-HEPES,
pH 7.5, 2 mM DTT, 4 mM ADP, 2 mM MgCl2, 17% PEG 8000, 1 M NaBr, 100 mM
MES, pH 7.5, and 25% glycerol.
The longest crystals grown using protein pre-mixed with 4 mM AMPPNP, pH
7.5, and 2 mM MgCl2 appeared using the well solution containing 12% PEG 8000, 1 M
NaCl, 100 mM Na-citrate pH 5.92 (Fig. 11G). These were clusters of needles and
nucleated in 3-4 days at 4 °C. Tiny crystals were also grown with 12-15% PEG 8000, and
1-1.2 M NaCl; 16% PEG 3350, and 1-1.2 M NaCl; and 14% PEG 6000, and 1 M NaCl,
all containing 100 mM Na-citrate buffer pH 5.92. None of these crystals were of
diffraction quality and were not harvested. The conditions need to be optimized to grow
thicker and single crystals.
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Figure 11. Different crystal forms of GRK1535-His6.
(A) Clusters of rod shaped plates were grown in the presence of 4 mM ATP and 2 mM MgCl2 at
4 °C. These crystals belong to the space group C2 and diffracted to 2.7 Å. (B) Rod shaped
crystals were also grown in the presence of 4 mM ATP and 2 mM MgCl2 at 4°C and belong to
P212121 space group and diffracted to 2.9 Å. (C) Hexagonal plates were grown at 4°C without any
nucleotide added to the protein solution. The crystals diffracted to ~8 Å. (D - F) Crystals were
grown in the presence of 4 mM ADP and 2 mM MgCl2 either at 20 °C (panel D) or 4 °C (E - F)
and diffracted to 1.85 Å (panel D), 2.63 Å (panel E) and 3.62 Å (panel F). (G) Sea-urchin shaped
crystals were grown at 4 °C with 4 mM AMPPNP and 2 mM MgCl2 added to the protein solution.
These crystals were not of diffraction quality.
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X-ray Data Collection
Diffraction maxima were collected from crystals labeled crystal form I-III at the
SBC 19ID (λ = 0.97967 Å) on an ADSC Q315 detector. For crystal forms IV-VI, data
were collected at the GM/CA-CAT 23ID-D beamline at the APS (Argonne National
Laboratory) on a MAR300 CCD detector (λ = 0.97934 Å). The crystals were cooled in a
cryostream at 100 K. The data was indexed, integrated and scaled using the HKL2000
software package [90]. The refined values of the unit cell and the mosaic spread are
summarized in Table 3.
Structure Determination and Refinement
Initial structure of GRK1 was determined using crystal form I. The data
harvesting program TRUNCATE [91] was used to generate structure factor amplitudes
from intensities. Matthew’s coefficient (Vm) was estimated to be 2.74 Å3/Da [92]
implying that there are two molecules in each asymmetric unit with a solvent content of
55.16 %. The Wilson B-factor was estimated to be 43.4 Å2.
The initial phase problem was solved by molecular replacement using the
program PHASER [91] in the CCP4 suite using GRK6 (PDB code: 2ACX) as a search
model. All the ligands were omitted from the search model. The r.m.s. deviation of model
with respect to the final structure was 0.8 Å with no clashes between trace atoms. The
unique solution at the end of each search was refined and an electron density map was
calculated. The Log-likelihood gain (LLG) score of the final solution was 1081.42. The
initial R-factor values of the structure were 34.6% (Rwork) and 41% (Rfree). The
coordinates were refined using TLS (Translation, Liberation and Screw-rotation) and
restrained refinement in REFMAC5 [91], alternating with rounds of manual rebuilding
using the program O [93]. Non-crystallographic restraints (NCS) were set up for the
different domains (excluding the N- and C-termini and the C-terminal extension of the
kinase domain) for both the monomers in the asymmetric unit. The coordinates for Mg2+
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and AMPPNP were taken from GRK6 and the atom name N3B in AMPPNP was changed
to O3B converting it to ATP. The ligands were manually fitted in the active site with |Fo-
Fc| map contoured at 3σ (Fig. 20). Electron density revealed phosphorylation of Thr8
residue, which was modeled as a phosphothreonine (TPO). Water molecules were added
using the O macro wat_add once the R-factors were close to 20 %. The water molecules
that were kept after refinement had the correct hydrogen-bonding stereochemistry and B-
factor values < 50 Å2. After Rfree converged, all reflections were used for the last few
rounds of refinement. The stereochemistry of the refined model was validated using
PROCHECK [91].
The phase problem for the other crystal forms was solved using either crystal
form I or IV as a search model, depending on whether ADP or ATP state was expected.
The data collection and final refinement statistics are summarized in Table 3.
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Table 3. Data collection and refinement statistics.
Crystal Form I II III IV V VI




370 371.2 628.8 252 350 400
Oscillation range (°) 360 130 130 360 180 360
Oscillation angle (°) 0.75 0.75 1 1 1 1
Exposure time (sec) 1 1 1 3 3 1
Mosaicity (°) 0.2-0.42 0.12-0.42 0.56-0.8 0.53-0.71 0.35-0.8 0.22-0.4
Dmin (Å) 2.7 2.9 7.51 1.84 2.60 3.55
Rsym b 9.6 (64.7) a 8.2 (43.7) 8.4 (79.1) 5.5 (49.5) 8.9 (51.2) 9.6 (47.9)
I/σI 22.9 (3.1) 10 (1.6) 24 (2.7) 35.1 (3.0) 19.8 (2.7) 17.4 (2.2)
Completeness (%) 99.7 (100) 96.2 (94.2) 100 (100) 99.4 (99.2) 99.8 (99.9) 97.6 (94.2)
Redundancy 6.8 (6.6) 2.2 (2.2) 7.2 (7.6) 4.2 (4.2) 5.8 (5.9) 3.6 (3.6)
Refinement
Resolution (Å) 20 - 2.7 20 - 2.9 20 - 7.51 20 - 1.84 20 - 2.60 20 - 3.55
No. reflections 36,930 (2,668)c 26,552 (1,822) 2,230 (156) 49,141 (3,591) 43,677 (3,124) 17,300 (1,185)
Rwork d 19.1 (27.7) 19.2 (29.5) 18.8 (42.8) 19.1 (24.3) 19.0 (27.9) 30.7 (35.8)
Rfree e 24.6 (31.9) 25.6 (35.0) 27.4 (44.4) 21.7 (26.7) 23.8 (32.9) 36.7 (37.8)
Rfinal f 19.2 (26.9) 19.2 (27.5) 18.2 (40.0) 18.9 (23.7) 19.0 (27.0) 28.7 (36.6)
Protein atoms 8156 7841 7629 4017 8,056 7841
Non-protein atoms 234 126 0 366 381 64
Wilson B factor (Å2) 64.2 72.9 ND 30.8 53.0 ND
Average B factor (Å2)
  Protein atoms 46.88 44.28 239.5 37.90 40.73 132.9
  Ligands 36.16 42.24 0 32.12 41.10 132.2
  Solvent 36.07 23.81 0 42.75 36.73 0
R.m.s deviations
  Bond length (Å) .011 .010 .007 .009 .010 .008
  Bond angles (°) 1.3 1.28 1.0 1.2 1.25 1.1
Ramachandran plot
  most favored (%) 92.5 90.8 79.5 92.3 90.0 83.5
  disallowed (%) 0.0 0.0 0.2 0.0 0.0 0.0
a Numbers in parentheses correspond to the highest resolution shell of data; Crystal Form I: 2.8-2.7 Å; Crystal Form II:
3.0-2.9 Å; Crystal Form III: 7.77-7.5 Å; Crystal form IV: 1.91-1.84 Å; Crystal form V: 2.69-2.60 Å; Crystal form VI:
3.68-3.55
b Rsym = ∑hkl∑i |I(hkl)i - I(hkl)|/ ∑hkl I(hkl)i, where I(hkl) is the mean intensity of i reflections after rejections.
c Numbers in parentheses correspond to the highest resolution shell of data; Crystal Form I: 2.77-2.7 Å; Crystal Form II:
2.97-2.90 Å; Crystal Form III: 7.68-7.51 Å; Crystal form IV: 1.89-1.84 Å; Crystal form V: 2.67-2.60 Å; Crystal form
VI: 3.64-3.55
d Rwork = ∑hkl||Fobs(hkl)| -|Fcalc(hkl)||/ ∑hkl |Fobs(hkl)|; no I/σ cutoff was used during refinement.
e 5% of reflections were excluded from refinement to calculate Rfree.
f All reflections were used during the last rounds of refinement.
ND = Not determined. Wilson B factors are not applicable for low resolution data sets.
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RESULTS
AIM 1: STRUCTURAL ANALYSIS OF GRK1
Production of functional GRK1535
The soluble GRK1 (labeled GRK1535-His6) elutes from Source S column in 4-5
major peaks (Fig. 12a) with each migrating to a different molecular weight on a SDS-
PAGE gel, even after incubation with ATP (Fig. 12 inset). The LC-MS/MS analysis
revealed that the mass of the major peak Pool A (Peak 1) corresponds to a full-length
acetylated GRK1535-His6 phosphorylated at one or two sites. The masses of Pool B (Peaks
2-3) and Pool C (Peak 4) were 820 Da and 1.7 kDa respectively smaller than Pool A,
suggesting that these result from proteolysis of Pool A (Table 4). The N-terminal
sequencing identified the truncation sites as residues Thr8 (Pool B) and Ala17 (Pool C) in
GRK1535-His6 (Table 4). Similar N-terminal truncations have not been reported for wild-
type GRK1 purified from retina [26, 94], baculovirus-infected insect cells [28] and
mammalian cells [27]. The loss of the C-terminal residues thus appears to render the
amino-terminus of GRK1 more accessible to proteases. In the wild-type enzyme, the N-
terminus could be protected either by direct interaction of its amphipathic helix with the
lipid-bilayer/detergent micelle, or with elements of the C-terminus that are missing in our
GRK1535 protein, or by the fact that membrane localization of wild-type GRK1 hinders
the approach of proteases.
The effect of the N-terminal truncations was assessed in ROS phosphorylation
assays. While Pool A was the most active (Fig. 13a) Pool C, which is the most N-
terminally truncated, phosphorylated rhodopsin poorly (Fig. 13c). Interestingly, Pool B
had significant activity, suggesting that the first seven residues were not critical but
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clearly facilitate the phosphorylation of activated receptors (Fig. 13b). The
autophosphorylation activity was similar for all pools (Fig. 13c) in agreement with a role
in receptor recognition for N-terminus. Steady state kinetics revealed that compared to
wild-type GRK1, Pool A phosphorylates ROS with a 6-fold higher Km (12 µM) and a 2-
fold lower Vmax, possibly because of defects in membrane targeting resulting from the
loss of its C-terminal farnesylation site (Table 6). These truncated proteins were also
tested for their ability to bind Ca2+·recoverin. Pool B exhibited reduced recoverin binding
whereas Pool C did not retain any observable affinity (Fig. 13d). Thus, our data is
consistent with residues 8-17 containing elements that are implicated in both receptor
function and recoverin binding. These residues span the most highly conserved region of
the GRK N-terminus.
- 57 -
Figure 12. Analysis of different peak fractions of GRK1535-His6.
(a) Source 15S elution profile of GRK1535-His6.  Pool A (peak 1) elutes at NaCl
concentration of 140-175 mM, Pool B (peaks 2-3) at 180-210 mM NaCl, and Pool C
(peak 4) at ~220 mM. A fifth peak (Pool D) corresponds to aggregated protein.  The inset
shows that Pool A and C fractions migrate differently on a SDS-PAGE, even after
incubation with Mg2+·ATP.  Pool A corresponds to full-length acetylated GRK1535-His6
with potentially one or two phosphorylations. (b) N-terminal immunoblot analysis.
Monoclonal rabbit GS19 antibody, which recognizes the residues 17-34 as epitope
reveals that atleast this region is intact in all the samples. (c) C-terminal immunoblot
analysis. GRK1535 construct was expressed as a His6 tagged protein at the C-terminus.
Western using Penta-His antibody (Qiagen) revealed that the C-terminus is intact in all
the three pooled peak fractions.
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Table 4. N-terminal sequencing and MS analysis of GRK1535-His6.
Sample N-terminus* Intact Mass
# (Da) Expected Mass|| (Da)
Pool A Acetylated (blocked) 61,390 and 61,488 61,390
Pool B Thr8 60,659 and 60,567 60,568
Pool C Ala17 59,672 59,665
*  N-terminal sequence analysis was performed on protein from two different
purifications. The analysis of Pool A failed because the N-terminus is blocked by
acetylation. The analysis revealed that Pool B and C are missing seven and 16 residues
respectively from the N-terminus.
# The masses corresponding to the major peaks in each sample are reported.
|| Expected masses were calculated based on the primary sequence of GRK1535-His6 after
taking into account the N-terminal acetylation (for Pool A) or N-terminal truncations (for
Pool B and C).
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Figure 13. Effects of N-terminal truncations on the activity of GRK1535-His6.
Protein amounts were normalized by SDS-PAGE and A280 measurements (>95% homogenous).
(a) ROS phosphorylation assays using 18 nM Pool A. The reactions were initiated by addition of
100 µM [γ-32P]ATP mixture (100-1000 cpm/pmol) and illumination at 30 °C. After 10 minutes
reactions were quenched using 10 % TCA. The Km for Rho* was estimated to be ~12 µM (see
Table 6). The values plotted are representative of 2-3 independent experiments, with two
measurements for each concentration of ROS. The data was analyzed using non-linear analysis
and curve-fitting programs of GraphPad Prism version 4.0a for Macintosh.  (b) Similar assays
using 18 nM Pool B in 100 µl reactions. Pool C (not shown here) phosphorylated Rho* poorly
and the steady state kinetic parameters could not be estimated under similar assay conditions. (c)
Pool A, B and C were analyzed at three different concentrations in 10 µl reactions, with 30 ng
kinase being equivalent to 50 nM. The reactions were set up the same way as in panel (a) or (b)
using 2.5 µM ROS and were quenched after 10 minutes by addition of SDS running buffer. The
dried gel was scanned and the bands were quantified using the ImageQuant software version 5.2
(Molecular Dynamics). Assays with no kinase added were used (lane labeled “Bl”) to check the
background signal from endogenous kinase contamination in the ROS sample. 10 ng GRK2 was
used as a control. The autophosphorylation activity is, however, similar. (d) Effect of N-terminal
truncations on the efficiency to bind Ca2+·recoverin. Approximately 50 µg GRK1535 samples
(LOAD) were incubated with unmyristoylated-recoverin coupled to Sepharose CL-4B beads. The
bound protein was eluted (BOUND) with a buffer lacking CaCl2. The unbound protein is in the
flow-through (FREE). Compared with Pool A, Pool B displays reduced binding whereas Pool C
has no detectable affinity for the column. The experiment was repeated twice, each with the
binding reactions performed in triplicate, as shown.
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Being the most active and abundant form, GRK1535 construct (Pool A) was co-
crystallized with different nucleotide ligands to yield five crystal forms, with two bound
to (Mg2+)2·ATP and three to (Mg2+)2·ADP. A sixth crystal form was grown in the absence
of any nucleotide ligands (Table 3). Together these allow us to compare three nucleotide-
ligand binding states of GRK1, represented by (Mg2+)2·ATP·GRK1 (substrate-bound),
(Mg2+)2·ADP·GRK1 (product-bound) and the apo-form. In five crystal forms, two
molecules of GRK1 are found in the asymmetric unit (Fig. 14a). In the highest resolution
crystal form (IV), only one subunit is found in the asymmetric unit yielding a total of 11
independent structures. In all crystal forms, GRK1 forms a dimer, with the interface
mediated by the RGS homology (RH) domain, as it was in GRK6 [63]. Although the
dimer interface is conserved in all crystal forms, the relative orientation of the dimer
subunits differ among the crystal forms. For example, the chain B of crystal form V
needs to be rotated by ~12° to align with that of crystal form I when their A chains are
first superimposed (Fig. 14b).
The overall quaternary structure of GRK1 (Fig. 14a) is similar to GRK2 and
GRK6. The RH-kinase core of GRK1 is comprised of bipartite interactions between the
RH and the kinase domain that are analogous to the contacts made by the SH2 and SH3
domains of inactive Src [95]. The total buried surface area is ~2,075 Å2 between the two
domains. The largest portion of the interface (1,360 Å2) is formed between the α0, α9
and α10 helices of the RH terminal subdomain and the α9-β1, β2-β3 and αC-β4 loops of
the small lobe of the kinase domain (Fig 14c). The interdomain interactions could
represent stabilizing interactions between the RH and kinase domains. The α10 helix
forms extensive contacts with the αC-β4 loop, which could help orient the αC helix of
small lobe that contributes residues to the nucleotide-binding pocket. The second, smaller
interface is formed between the α4-α5 loop of the RH bundle subdomain and the αJ
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helix, the first element of the kinase C-terminal extension (Fig. 14d). The role of this
interface is not known, but it could represent a stabilizing interaction for the C-terminal
extension of the kinase domain. This latter interface is maintained in all crystal forms
except in apo-GRK1, where it appears altered or disrupted as a direct consequence of the
distinct kinase domain conformations observed in this crystal form. Otherwise, the RH-
kinase core of the 9 nucleotide-bound structures of GRK1 are quite similar (0.4-0.9 Å for
equivalent Cα atoms), with the regions of greatest conformational variability being the
α6-α7 loops of the RH domain and portions of the kinase C-terminal extension, in
agreement with their relatively high B-factors (Fig. 15).
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Figure 14. The RH-Kinase Core of GRK1.
(a) The dimer of GRK1 observed in all the crystal forms. The dimerization is mediated by a
conserved interface of the RH domain. The dimer shown here is of the most complete structure of
GRK1 (crystal form I). The terminal subdomain of the RH domain (helices α0-α3 and α8-α11) is
colored violet while the bundle subdomain (α4-α7) is colored slate. The small lobe of kinase
domain (yellow) is composed of 6 β-strands (orange) and 2 α-helices (αB and αC), while the
large lobe is primarily α-helical. The ligand (Mg2+)2·ATP is drawn as spheres. Magnesium atoms
are colored black, carbons white, nitrogens blue, oxygens red, phosphates orange and chloride
ions cyan. The extreme N-terminal region and the C-terminal extension of the kinase domain are
colored green for emphasis, as these were not previously observed in GRK2 and GRK6 crystal
structures [60, 61, 63]. (b) The dimer-related kinase domains differ by 12° between the crystal
forms I and V, revealing the flexibility of the dimer interface. Crystal form I is colored yellow
and crystal form V is orange. The orientation is the same as in panel (a). The grey line and the
arrow indicate the direction of the rotation axis. (c) The RH-small lobe interface as seen in the
crystal form I (chain B). The symmetry-related residues 24-32 form extensive crystal contacts
(brown) that appear to stabilize the conformation of the N-terminus in this crystal form. (d) The
RH-large lobe interface consists of a salt-bridge between Arg458 (αJ helix) and Asp100 and
hydrogen bonds with the backbone of the α4-α5 loop of the bundle subdomain. The side chains
shown are conserved in all GRKs except GRK2 and GRK3 (Fig. 19).
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Figure 15. Average backbone B factors.
The average main chain B factors for crystal form IV and chain B of crystal forms I and
V are shown as a plot of the average main chain B factors as a function of residue
number, with gaps corresponding to disordered residues. Regions of interest with
relatively high conformational flexibility have been labeled.
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N-terminus of GRK1
The amino-termini of GRKs have been shown to contain residues that regulate
receptor phosphorylation [45, 49, 57]. Up until now, this critical region (residues 1-30)
has been disordered in each GRK structure determination [60, 61, 63]. One of the
(Mg2+)2·ATP·GRK1 crystal forms (chain B of crystal form I) reveals residues 5-30 (Fig.
16a and c). However, the structure is disordered in the other 10 structures of GRK1,
wherein the electron density can be traced starting at either Ala29 or Ser30 or Arg31. The
N-terminus forms extensive contacts with the two RH sub-domains with a total buried
surface area of ~1,200 Å2. The residues 1-4 are not ordered and appear to thread the hole
formed by the bipartite interface between the RH and kinase domains. Residues 5-12
wander through the cleft formed between the bundle and terminal lobes of the RH
domain. This cleft is used to bind adenomatous polyposis coli (APC) peptide in the RH
domain of axin (Fig. 3) [62]. The electron density maps reveal that Thr8 residue is
phosphorylated (Fig. 16b) and the side chain of phosphothreonine residue is coordinated
by Gln73 and Glu93 residues (residues in the α4 helix). The hydrogen bond formation
will be favored as the crystals were grown at a pH of ~4.35 when the carboxyl groups and
the phosphate ion could be protonated. In addition, the two lysine residues (Lys69 and
Lys93) in the vicinity could complement the charge on the phosphate. Residues 13-23
form a helix (αN) whose side chains interact primarily with backbone atoms in the RH
terminal subdomain. Based on the electron density maps the Ser21 residue, one of the
known phosphorylation sites in GRK1 [38, 81], does not appear to be phosphorylated.
Residues 24-32 form a loop that is engaged in an extensive crystal contact. This loop
region is variant in GRKs and links the N-terminus to the α0 helix of the RH domain.
The observed N-terminal structure is not dependent on phosphorylation of the N-
terminus, but appears to be stabilized by the crystal contacts (Fig. 16c). Analogous crystal
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contacts are lacking in the other crystal forms, including crystal form II (grown in the
presence of ATP) wherein the N-terminus is not ordered. The phosphorylation at Thr8
residue led us to analyze the site by phosphoamino acid analysis of trypsinized N-
terminal fragments. Phosphorylation of Thr8 was detected in GRK1535-His6 pre-treated
with ATP but not in GRK1 isolated directly from bovine retinas, suggesting that the
phosphorylation results from incubation with ATP. Ser21 residue which, is now believed
to be a PKA site [81], had detectable phosphorylation in both the samples. Unexpectedly,
the analysis detected phosphorylation of Ser5 in both the endogenous and in vitro
samples (Fig. 17). The physiological role of these novel sites (Ser5 and Thr8) was
assessed by steady-state kinetics (see Specific Aim 2).
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Figure 16. The Most Complete Structure of GRK1.
(a) The RH-kinase core of GRK1 (represented by crystal form I). For this figure, the
coordinates of all the GRK1 crystal forms were merged to generate a structure that spans
residues 5-533 (out of 558), and the large lobe was rotated to generate the expected
closed, active state analogous to that of PKA [96]. The Ser5, Thr8, Ser21, Ser488 and
Thr489 phosphorylation sites are drawn as stick models. The expected position of the
membrane plane is indicated. The red arrows indicate the N-terminal truncation sites
mapped on the structure (refer to Table 4). The coloring scheme is as in Fig. 14a. Top
inset. The Ser488 and Thr489 phosphorylation sites correspond to the AGC kinase “turn
motif” and although not observed in the structure are expected to form electrostatic
interactions with the charged residues in the αB helix of the kinase domain. Bottom
inset.  Interaction of phospho-Thr8 with the RH domain.  Gln73 and Glu93 form direct
hydrogen bonds, while Lys69 and Lys90 complement the charge of the phosphate
moiety. (b) A σA-weighted |Fo|-|Fc| map contoured at 3 σ at the N-terminus. The N-
terminal residues 5-30 were excluded from refinement. The polypeptide backbone
representing the first six residues is shown here for clarity, highlighting the density of
phospho-Thr8. The carbon atoms colored green, oxygens red, nitrogens blue and
phosphorus orange. (c) The structural alignment of the N-termini of GRKs. The numbers
on top indicate the residue number in GRK1 sequence. The accession codes for the
protein sequences are: GRK1, P28327; GRK2, NP_777135.1; GRK3, P26818; GRK4,
AAI17321.1; GRK5, P43249; GRK6, P43250; GRK7, NP_776757.1.
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Figure 17. Phosphorylation sites identified by LC-MS/MS analysis.
(a) Ser5 is phosphorylated in bovine GRK1 isolated from retinas. (b) Ser5 and Thr8 are
phosphorylated in GRK1535 pre-incubated with 4 mM ATP and 2 mM MgCl2. (c) Ser21





RGS Homology Domain of GRK1
The conformation of RH domain is maintained in all the crystal forms with
r.m.s.d. of 0.4-0.9 Å (Fig. 18a).  Similar to GRK6, the RH domain of GRK1 contains a
α0 helix at the N-terminus [63] that mediates contacts with both the RH and the kinase
domains but does not contribute to the hydrophobic core of either domain (Fig. 18b).
Unlike GRK2 and GRK6, the α6 -α 7 loop is not well-ordered in GRK1. The
superposition of the kinase domains of GRK1, GRK2 and GRK6 reveals that the RH
domains of GRK1 and GRK6 are deported similarly with respect to the kinase domain
(r.m.s.d. of 1.04 Å for equivalent Cα  atoms), consistent with their closer sequence
homology to each other than to GRK2 (GRK1 and GRK6 share ~34 % sequence identity
as opposed to 24% to GRK2).  The RH domain of GRK2 is rotated ~11˚ with respect to
that of GRK1, with the axis of rotation running along the RH-small lobe and the RH-
large lobe interfaces (Fig. 18c).
The RH domain of GRK2 (α5 and α6 helices) makes “effector” like contacts with
the Gαq subunit [61]. The RH domain in other GRK sub-families has not been reported to
bind any Gα subunit. The structural comparison suggests that this could be because the
α5 helix is ~ 2 turns shorter in GRK1 (Fig. 18c) and hence lacks the residues critical for
binding Gαq subunit in GRK2. However, the RH domain of GRK1 forms an extensive
dimer interface with a buried accessible surface area of ~2,800 Å2 (Fig. 18d). The
interface is seen in five crystal forms and a similar dimer exists in the ADP-bound crystal
form IV along the crystallographic 2-fold axis. The residues contributing to the dimer
interface are conserved in GRK1 and GRK4 sub-families (Fig. 19) and the interface
could mediate protein-protein interactions in vivo. Preliminary investigations into the
physiological role of this interface were performed by steady-state kinetic assays (see
Specific Aim 2).
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Figure 18. GRK1 RH Domain.
(a) Superposition of RH domains from different crystal forms of GRK1. The kinase domain
(yellow) is shown for reference. (b) The RH domain of crystal form I (chain B) in the same
orientation as in panel a. (c) The kinase domains of GRK1 (slate) and GRK2 (red) were aligned in
this figure to highlight the differences in the orientation of the RH domain in these two GRK sub-
families. The kinase domain of GRK2 is not shown for clarity. Note that the α5 helix is extended
in GRK2. (d) The dimerization interface mediated by the RH terminal subdomain. The terminal
subdomains have been colored slate and magenta to represent the two monomers. The side chains
of Trp531 and Tyr167 form stacking interactions with their dimer equivalents, and Asp164 forms
a hydrogen bond with the backbone of the opposing monomer. The Leu166 and Leu44 side
chains also contribute to the hydrophobic core of the interface. The residues contributing to the
interface are conserved in GRK1 and GRK4 sub-families, but not in GRK2, which lacks this
interface.
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Figure 19. The structural alignment of RH domains of GRKs.
The numbers above the sequence alignment indicate the residue number in GRK1. The
terminal and bundle subdomains are colored magenta and slate respectively. The
sequence corresponding to the kinase domain (sandwiched between the α9-α10 helices)
is not shown in this alignment and is represented by the dots.  The α5 helix that is
extended in GRK2 [61] with respect to GRK1 and GRK6 [63] is indicated with a
translucent helix. The α6-α7 loop is not well-ordered in the GRK1 structures (colored
brown). The residues that are structurally variant are colored grey. The residues that form
the crystalline dimer interface are colored orange. The green asterisks below the sequence
alignment indicate positions of the residues that form the bundle-large lobe interface. All
the GRK sequences are bovine, except GRK4 and GRK6. The accession codes for the
protein sequences are: GRK1, P28327; GRK2, NP_777135.1; GRK3, P26818; GRK4,
AAI17321.1; GRK5, P43249; GRK6, P43250; GRK7, NP_776757.1.
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GRK1 Kinase Domain
The kinase domain of GRK1 shares 39-55% identity with the other 6 members of
the GRK family and ~34 % sequence identity to those of other AGC kinases such as PKA
and PKB.  The kinase domain is comprised by a “small lobe” (residues 181-268) and a
“large lobe” (residues 269-454) with the active site situated in the cleft between the two
lobes. Even though GRK2 and GRK6 were co-crystallized with nucleotides or their
analogs, the nucleotide was not well ordered [60, 61, 63, 97] and their kinase domain
crystallized in an “open” conformation similar to the “open” inactive structures of PKA
[98].
Nucleotide Binding and Conformational Changes
In all the nucleotide-bound structures of GRK1 both ATP and ADP are well
ordered and the binding is analogous to that of AGC kinases wherein the conserved
catalytic Lys216 residue (β3 sheet) coordinates with the phosphates of nucleotide. The
active site of the nucleotide-bound structures is characterized by the presence of two
Mg2+ ions except in the chain A of crystal form I and II wherein the Nζ atom of Lys497
residue from a symmetry-related molecule displaces one of the Mg2+ ions inducing an
unusual C2’-endo conformation of the purine ring (Fig. 20a). In the ATP complex, the
first metal ion coordinates the β and γ, and the second metal ion the α and γ phosphates
(Fig. 20b).  In the ADP complex, the metal ions coordinate the β, and the α  and β
phosphates, respectively (Fig. 20c). Thus, the active site of the (Mg2+)2·ATP complex of
GRK1 closely resembles that of the PKA·(Mn2+)2·ATP complex [99], while the ADP
complex resembles the Aurora-A·(Mg2+)2·ADP complex [100].
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Figure 20. Electron density omit maps of the nucleotide binding site.
(a) The substrate complex of GRK1 contoured at 4σ, wherein ATP, Mg2+ (black) and
associated waters (green) were excluded from refinement (chain A, crystal form I).
Lys216 (β1 sheet, orange carbons) coordinates the α- and β-phosphates of ATP and
ADP. Glu332 (yellow carbons) coordinates both Mg2+ atoms close to the phosphates of
the nucleotide. In this ATP·GRK1 structure, the structural Mg2+ ion in the active site is
displaced by the Nζ atom of Lys497 (green carbons) donated by a crystal contact. As a
consequence, the ribose sugar of ATP displays the C2'-endo conformation as opposed to
the C3'-endo conformation observed in the other GRK1 nucleotide complexes (b and c).
(b) The substrate complex of GRK1 contoured at 4σ (chain B, crystal form I). Asn319,
which coordinates the structural Mg2+, was omitted for clarity. (c) Product complex of
GRK1. A σA-weighted |Fo|-|Fc| omit map contoured at 5σ, wherein ADP, Mg2+ and
associated waters were excluded from refinement (crystal form IV).
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In AGC kinases, the β1-β2 loop (small lobe) contains the glycine-rich conserved
GxGxFG motif (residue 194-199 in GRK1) that forms the phosphate-binding loop (“P-
loop”). Nucleotide binding is associated kinase domain “closure” that involves
reorientation of the Gly-rich P-loop and the active site residues that make contacts with
the ribose moiety and the phosphate group of ATP. Although the substrate binding site is
preformed, “closure” of the kinase domain is associated with exclusion of water
molecules from the active site and orientation of residues in the αD helix and the αF-αG
loop that are implicated in substrate binding. The tip of the P-loop is still dynamic and
moves closer to the catalytic site when peptide substrate docks onto the large lobe and
mediates contacts with the small lobe [96, 98, 99, 101]. Comparison with the “active”
structure of PKA reveals that in GRK1 the P-loop is shifted by ~2.3 Å away from the
nucleotide binding site. The conformation of this loop in the different nucleotide-bound
structures of GRK1 is similar to that in nucleotide-free GRK2 and AMPPNP-bound
GRK6 structures [60, 61, 63, 97]. The structural difference in GRKs could result from
GRK-specific substitutions in the adjacent αB helix. In GRKs there is a conserved
glycine residue (Gly228 in GRK1), which is substituted by a bulkier residue in other
AGC kinases (Gln84 and Glu193 in PKA and PKB respectively). The presence of a
smaller residue would allow the Phe198 residue (in the P-loop) to pack against the αB
helix. Thus, there is no evidence of a conformational change in the P-loop in GRKs upon
binding to nucleotide substrates. Since the “regulatory” kinase C-terminal extension
packs near this region it is possible that this site could be involved in mediating
interaction of GRKs with the activated GPCRs. In the receptor-docked kinase, the P-loop
may adopt a conformation similar to that in the “active” transition-state PKA structure
[96].
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In case of GRK1, the various nucleotide bound kinase domains adopt a similar
conformation with r.m.s.d. values of 0.3-0.71 Å for equivalent Cα atoms.  Interestingly,
the kinase domains of apo-GRK1 have a distinct conformation from each other and from
the nucleotide bound structures (dictated, in part, by unique crystal contacts) suggesting
that in the nucleotide free state the kinase is conformationally flexible and that the
presence of ATP or ADP stabilizes the domain. This is in agreement with the observation
that the apo-GRK1 crystals diffract poorly. Even though the apo structure of GRK1 is a
low resolution structure it is still informative when considering the differences in the
relative orientation of the two lobes of the kinase domain. The superposition of the small
lobes of various ATP and ADP bound forms with those of the apo-GRK1 reveal that
nucleotide binding leads to a ~ 8° (Fig. 21a) closure of the kinase domain but even so, the
active site catalytic machinery is still not properly aligned.  The catalytic base Asp314 is
~3 Å away from the γ-phosphate when compared to the structure of ADP·AlF3 bound
transition state complex of PKA [96]. Thus, nucleotide binding alone is not sufficient to
provide the free energy required for domain closure. Superposition of the small lobes
reveals that an additional ~13-15° rotation of large lobe is required (along an axis running
roughly parallel to and between the αD and αE helices) to attain the “closed” active
conformation (Fig. 21b) (Table 5). The required domain closure leading to activation of
the kinase could be achieved when GRKs dock to an activated GPCR.
Structural Comparison of the Kinase Peptide-Binding Channel
By analogy to the AGC kinases, the peptide-binding surface lies on the large lobe
adjacent to the nucleotide-binding site with αD-αE and αF-αG loops forming the walls
of the channel. Comparison with PKA structure reveals that both these loops are longer in
GRKs (a 4-residues insertion in GRK1) and hence adopt distinct conformations. The
binding of Glycogen Synthase Kinase 3β (GSK3β) peptide to the large lobe of PKB
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(PDB 1O6L) reveals that the peptide-binding channel is wider in GRK1, reflecting its
more “open” conformation (Fig. 21e,f). The phosphoacceptor oxygen is > 4 Å away from
the γ-phosphate of ATP, which is too far to achieve catalysis. In addition, the N-terminus
of the modeled peptide is obstructed by the αF-αG loop. This was also observed in the
GRK6 structure. Thus, either the peptide substrates bind GRKs in a distinct manner or the
channel might assume a different conformation when docked to a receptor. The
electrostatic surface representation reveals that the channel bears an overall basic
character, which may explain why GRK1 prefers acidic substrates.
- 81 -
Figure 21. The structural comparison of the GRK1 kinase domain.
(a) The kinase domain adopts a similar conformation in the various nucleotide-bound
ligand states of GRK1. The kinase C-terminal extension is not modeled in this figure, for
clarity. (b) The small lobe of the transition state PKA complex (magenta) was aligned
with that of the GRK1·(Mg2+)2·ADP (green) complex to compare the relative orientations
of their large lobes.  The brown circle indicates the position of the rotation axis (coming
directly out of the figure) around which the large lobe of GRK1 would have to rotate 15˚
to assume the same conformation as PKA. (c) A rotation of ~ 8° is associated with
nucleotide-binding in GRK1. (d) The conformation of the apo GRK1 (chain A) structure
(orange) is more similar to the GRK6·Mg2+·AMPPNP (cyan). (e) The peptide binding
channel of GRK1. The channel has a strikingly basic character, explaining why GRK1
prefers acidic substrates [102, 103] and how it can phosphorylate multiple closely spaced
Ser and Thr residues at the C-terminus of Rho*. The channel is also wider in GRK1 than
in nucleotide-bound PKB (see panel f). A model of residues 332-345 from the C-terminus
of Rho*, is shown as a stick model docked to the large lobe with Ser338 in position to be
phosphorylated (position “+0”). The molecular surface of GRK1 is colored by its
electrostatic potential from -7 (red, acidic) to +7 (blue, basic) kT/e-. (f) The GSK3b
peptide bound to PKB. The PKB kinase domain (PDB code 1O6L) is in its closed
conformation and thus the channel is much narrower. The channel is acidic and the
kinase has a preference for basic substrates.
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Table 5. Comparison of kinase domains.
Rotation of large lobe relative to small lobe required to achieve a conformation similar to
the closed state of PKA.
PKAc PKBc PKAo PKBo I II IIIa IIIb IV V VI GRK2 GRK6
PKAc 0 4 13 13 14 13 20 12 15 13 15 20 17
PKBc 0 129 29 110 108 130 132 103 107 109 97 120
PKAo 0 100 20 24 8 20 29 26 24 32 14
PKBo 0 81 79 101 103 74 78 81 68 91
I 0 5 20 27 10 8 8 13 11
II 0 22 26 5 3 4 14 12
IIIa 0 12 27 23 21 33 10
IIIb 0 31 26 23 39 15
IV 0 4 7 11 17
V 0 3 15 13
VI 0 17 11
GRK2 0 24
GRK6 0
The “c” and “o” subscripts refer to the “closed” (catalytic) and “open” conformations of
PKA and PKB.  PKAc = PDB code 1L3R; PKAo = 1CMK; PKBc = 1O6K; PKBo =
1MVR. I-VI refer to the different crystal forms of GRK1. For GRK1 and GRK6, the
sequence analyzed corresponds to the “A” chain of their structures unless otherwise
specified.  Red numbers are the degrees required to superimpose the kinase large lobe of
each of these structures with that of PKAc.  All other values indicate the difference in
degrees between the rotation axes required to superimpose the large lobes, as determined
by the direction cosines of each of the rotation axes.  Hence, small values indicate that the
rotation axes are similarly oriented, and large values indicate large discrepancies (e.g. 90˚
indicates they are orthogonal).  Not all the rotation axes intersect.  The GRK rotation axes
required to achieve the closed conformation are quite similar and intersect (with the
exception of crystal form III) while those required to close the domains of PKA and PKB
are unique.  Note that among the GRK1 rotation axes, those of the apo-GRK1 (crystal
form III) are the most divergent (yellow highlights).  They are most similar to, although
significantly different from, each other (blue highlight), indicating not only a large degree
of flexibility in apo-GRK1, but also a discrete conformational state.  The conformation of
the apo-GRK1 domains are most similar to those of GRK6 (2ACX, grey highlights).
- 84 -
GRK1 Kinase C-terminal Extension
The residues 455-511 span the kinase C-terminal extension of GRK1, a region
that plays a regulatory role in non-GRK AGC kinases. The kinase extension has been
divided into three different elements: the C-terminal (large) lobe tether (CLT; residues
455-471 in GRK1), an active site tether (AST; residues 472-480) and N-terminal (small)
lobe tether (NLT; residues 498-511). While the CLT and the NLT were observed in
GRK2 and GRK6, no structural information is available for AST of GRKs. Together with
other elements of the C-terminal extension, the AST is thought to coordinate the
nucleotide and peptide binding with domain closure thereby activating the kinase [64].
The GRK CLT is structurally analogous to those of PKA and PKB, but uniquely
interacts with the adjacent RH domain. The AST contributes residues to the nucleotide
binding site and is disordered in structures of PKA that lack ligands in the active site.
This is true for GRK1 structures, as the AST was observed in only the ATP or ADP
bound structures, except when displaced by crystal contacts (in one chain of crystal forms
I, II and VI) (Fig. 22b). The GRK1 AST begins with the “tail loop” (residues Asp472-
Tyr477), which is 4 residues shorter than the analogous loops of PKA and PKB (Fig. 2b).
The tail loop lies in close proximity to the active site and packs adjacent to the hinge
connecting the two lobes of the kinase domain. The side chain of GRK1-Tyr477 (Tyr473
in GRK6, Tyr438 in PKB, Asn478 in GRK2 and Asn326 in PKA) forms a hydrogen
bond with the backbone nitrogen of the first residue of the tail loop (Fig. 22a). The next
residue, Ala478, is conserved as phenylalanine in all non-GRK AGC kinases, wherein the
aromatic side chain contributes to the adenine binding pocket. Interestingly, whereas
mutation of this residue in PKA (F327A) has been shown to render the kinase
catalytically inactive [104], in GRKs this residue is conserved as either an alanine or a
cysteine.  The striking lack of a phenylalanine at this position may help render GRKs
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catalytically silent until receptor binding. The side chain of the next residue, Lys479
(GRK1), extends towards the peptide-binding channel where it could interact with an
acidic peptide substrate. These features suggest that the GRK1 AST will be one of the
key elements involved in receptor-mediated activation and the phosphorylation of
polypeptide substrates.
Residues 481-489 of GRK1, which connect the AST to the NLT, wander over the
surface of the β1-β2 strands and αB helix of the small lobe. This region, however,
follows several distinct paths among GRK1 structures that are, at least in part, dictated by
unique crystal contacts. However, in every case the path is distinct from those of PKA
and PKB, consistent with this region being poorly conserved among AGC kinases.
Although the backbones of Ser488 and Thr489 (autophosphorylation sites) are visible in
some structures, high temperature factors (Fig. 15) prevent interpretation as to whether
they are phosphorylated in the crystal, even though the presence of phosphorylation at
both sites was detected by mass spectrometry in ATP-treated GRK1535-His6 (Fig. 17d).
These residues map to the “turn motif” of AGC kinases. Phosphorylation of this site in
PKC stabilizes the kinase and enhances activity. Indeed, given their location on the
surface of GRK1, Ser488 and Thr489 phosphorylation may permit stabilizing
electrostatic interactions with Arg222 and Lys221, respectively in the αB helix (Fig. 16a
inset).
The last element of the kinase extension, the NLT (residues 490-511 in GRK1,
(Fig. 22b) follows a common path in all GRKs, and its extreme C-terminus (502-511) is
structurally analogous to those of PKA and PKB with the motif contributing a final, short
β10 strand to the small lobe of the kinase domain in both GRKs and PKB. The GRK1
NLT contains the hallmark hydrophobic motif, but lacks the phosphorylation site
characteristic of PKB and PKC, presumably because the immediate re-entry of the
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polypeptide chain to begin α10 of the RH domain keeps this motif fixed in place in lieu
of phosphorylation.
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Figure 22. The kinase C-terminal extension of GRK1.
(a) The AST regions of GRK1 and PKB. For this comparison, the coordinates of the
various GRK1 crystal forms were merged to generate a composite structure of GRK1 that
spans residues 5-533 (out of 558), and the large lobe was rotated to generate the expected
closed, active state. The kinase C-terminal extension of PKB is grey, and the GSK3β
peptide bound to PKB is cyan. The “tail-loop” of GRKs is 4 residues shorter than those
of either PKB or PKA, resulting in formation of a shallow canyon with the hinge of the
kinase domain at the bottom. This region forms a putative receptor-docking site
(transparent ellipse). (b) Structural alignment of the kinase C-terminal extension of GRKs
with PKA and PKB. The alignment was carried out using ClustalW followed by manual
alignment of the residues corresponding to the active site and the C-lobe tether. The
region immediately following the AST is structurally divergent among GRKs, PKA and
PKB and thus no alignment is attempted. The numbers above the alignment refer to the
sequence of bovine GRK1. The different segments of the C-terminal extension that were
observed in each of our crystal forms are indicated below the alignment, with the black
regions corresponding to structurally heterogeneous portions in each structure that appear
influenced by crystal contacts.  Accession codes for the protein sequences are: GRK1,
P28327; GRK2, NP_777135.1; GRK3, P26818; GRK4, AAI17321.1; GRK5, P43249;
GRK6, P43250; GRK7, NP_776757.1; PKA, 1L3R; PKB, 1O6L.
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AIM 2:  FUNCTIONAL ANALYSIS OF GRK1
The structures of GRK1 along with mass spectral analysis identified
phosphorylation of GRK1 at several previously unidentified sites (Ser5 and Thr8). In
addition, the RH domain was observed to form a dimer interface in all the six crystal
forms. Using site-directed mutagenesis, roles of the N-terminal residues (Ser5 and Thr8)
and the residues at the dimer interface were tested in the steady state kinetics assays in
context of the full-length protein. The soluble fraction of wild-type GRK1 was chosen for
the initial studies, as there was sufficient amount of material available. Based on the time
course of Rho* phosphorylation, a 10 minute end point was chosen so that the rhodopsin
phosphorylation was in a linear range (Fig. 23a). Initially, GRK1 wild-type and mutant
proteins were purified in separate soluble and the membrane fractions, as the latter is
expected to be farnesylated at the C-terminus. However, the steady state kinetics revealed
that the Km for Rho* were similar (2-4 µM) for both fractions of the protein. Thus, some
of the proteins used in the assays were purified as a mixture. Based on the kinase
titrations, the assays were conducted using either 18 nM soluble fraction of GRK1 (Fig.
23b) or 8 nM membrane fraction or a mixture of both (Fig. 23c).
Phosphorylated N-terminus
Evidence for phosphorylation at Ser5 and Thr8 sites has not been reported so far,
although it has been suggested that GRK1 can incorporate 3-4 phosphates by
autophosphorylation [25].  Because these sites were in the critical N-terminus of GRKs,
we investigated whether the activity of GRK1 would be affected if these residues were
mutated to an alanine or aspartate/glutamate (to mimic constitutively phosphorylated
residues) by site-directed mutagenesis. The expression of T8D mutant was poor and the
S5D mutant was unstable when purified. This was observed even when different batches
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of baculoviruses were used for protein expression. As a result, the effect of these mutants
could not be tested. The S5A, T8A and T8E mutants phosphorylated Rho* similarly to
the wild-type GRK1 (Table 6). Thus, these in vitro assays did not reveal any significant
effects of the N-terminal phosphorylations.
Analysis of the crystalline dimer interface
Although GRK1 is monomeric in solution based on size exclusion
chromatography and analytical ultracentrifugation, we tried to assess the physiological
significance of the interface as all the six crystal forms of GRK1 were observed to be
dimers analogous to that formed by GRK6 [63]. Interestingly, rhodopsin is also predicted
to form dimers and higher oligomers [105]. Using site-directed mutagenesis, single
(D164A, L166K and W531A) and double mutations (D164A/L166K, D164A/W531A
and L166K/W531A) were introduced in wild-type GRK1, all of which disrupt the key
interacting residues in the dimer interface. The kinetic properties of D164A and L166K
mutants alone and in combination towards Rho* were similar to those of wild-type
GRK1 (Table 6). All the W531A-containing single and double mutants were however,
unstable and could not be purified to homogeneity suggesting that this residue plays a
structural role.
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Figure 23. Steady state kinetics.
(a) The time course assay using 50 nM wild-type GRK1 (soluble fractions) and 20 µM
ROS. Based on this curve, a 10 minute end point was picked as rhodopsin
phosphorylation remains in the linear range. (b) The kinase titration using varying
amounts of soluble wild-type GRK1 and 20 µM ROS as a substrate. Based on this curve,
we picked 125 ng kinase (~18 nM) for assays. (c) Similar assays as in (b) but for
membrane fraction of wild-type GRK1. Similar curves were obtained when a mixture of
soluble and membrane fraction of GRK1 was used. (d) A plot of a reaction using GRK1
wild-type in the assays as a reference. The data for wild-type GRK1 and the mutants has
been summarized in Table 5. Two measurements were taken for each concentration of
ROS in 2-3 independent assays. The signal from GRK1 autophosphorylation is negligible
because of the low amounts of kinase used in these assays.
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Table 6. Kinetic Analysis of GRK1
GRK1535-His6 Km (µM)† Vmax (nmol Pi/min/mg) †
Pool A 12±1.5 1100±46
Pool B 5.5±1.0 16±0.80
















† Results are listed as means ± S.D for two to three independent experiments, with two
measurements for each concentration of ROS (1-40 µM). The kinase was assayed at 18
nM (soluble fraction) or 8 nM (membrane fractions and protein purified as a mixture) in
100 µ l reactions. The protein amounts were normalized by SDS-PAGE and A280
measurements (>95% homogenous). The data was analyzed using non-linear analysis and
curve-fitting programs of GraphPad Prism version 4.0a for Macintosh.
‡ ND = not determined. These mutants either did not express or were unstable.
* These steady-state kinetic parameters could not be estimated owing to poor Rho*
phosphorylation. However, the initial rate of Pool C was estimated to be ~20-fold lower
than Pool A under similar assay conditions.
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Chapter 2. GRKs and Calcium Sensing proteins
INTRODUCTION
Calmodulin and recoverin belong to a class of proteins called calcium sensor proteins
(CSP) that undergo a conformational change upon binding calcium and have regulatory
functions. Recoverin, a 23 kDa myristoylated protein with four “EF hands”, is localized
to the vertebrate photoreceptor cells and is highly selective for GRK1 [29]. In the
calcium-bound state, recoverin undergoes a conformational change that forms a
hydrophobic cleft on the surface of the protein that can bind residue 1-15 of GRK1 [58,
106] (Fig. 24). Recoverin modulates GRK1 activity in vitro, in a calcium dependent
manner [30], although the affinity for calcium is low (Kd = 2-13 µM) [107, 108]. It was
proposed that this interaction prolongs the photoresponse by preventing the
phosphorylation of Rho* by GRK1 without affecting the intrinsic kinase activity of
GRK1 [58, 109]. The physiological significance of this interaction in vivo is not clear as
the phosphorylation of Rho* in permeabilized rods and intact retina is not affected by the
levels of calcium [110, 111]. It is now believed that recoverin plays a major role at the
synapse where Ca2+ is a known regulator of the release of neurotransmitters [112].
Calmodulin is a ubiquitous protein and a universal regulator of GRKs. GRK5 is
very sensitive to Ca2+·CaM  (IC50 in nM range) while GRK2 and GRK1 are affected at
high concentrations (IC50 in µM range or higher) [113]. Interaction with calcium bound
CaM appears to block membrane binding and this leads to inhibition of receptor
phosphorylation by GRK5. This hypothesis is supported by the observation that the CaM
binding site on GRK5 overlaps with the PIP2 binding site. The CaM binding site have
been mapped to both the N- and the C-terminus of GRKs and are not been well-defined
for GRK6 [109].
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Figure 24. NMR structure of GRK1 peptide bound to Ca2+·recoverin.
Recoverin, a calcium sensing protein, contains four helix-loop-helix motifs (four EF
hands) with EF-1 (wheat) and EF-2 (slate) forming the N-domain and EF-3 (green) and
EF-4 (salmon) forming the C-domain. The calcium ions are shown as orange colored
spheres. Compared to calmodulin and other calcium-binding proteins, recoverin contains
extra residues at the N- and C-terminus and an insertion (yellow and grey helices)
between the EF-3 and EF-4 hands. In addition, recoverin lacks an extended α-helical
insertion between the N- and C-domain and hence forms a more compact structure as
opposed to a dumbbell (as seen in calmodulin). The N-terminal helix (yellow) is usually
disordered or is sequestered in a calcium free state.  In calcium-bound state the helix is
extruded (calcium-myristoyl switch) and recruits recoverin to the membrane. This also
exposes a hydrophobic surface on the protein in the N-domain that binds GRK1
(magenta).  (PDB accession code: 2I94).
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Project Goals
Determine the structure of Ca2+·calmodulin·GRK6
The amino-terminus of GRKs has been implicated in receptor recognition and/or
activation [45, 49, 57]. In the crystal structure of human GRK6 (PDB code 2ACX) this
region of the protein was disordered. The aim of this project was to isolate and crystallize
a complex of GRK6 with calmodulin. The crystal structure of GRK6·calmodulin complex
would help in predicting the structure of the N-terminus of GRK6 and would also help
map the calmodulin-binding sites on GRK6.
Determine the structure of Ca2+·recoverin·GRK1
 The second aim of this project was to isolate a complex of GRK1 (GRK1535-His6
construct) and recoverin for structural studies. The structure of this complex would reveal
the structure of the amino-terminus of GRK1 in the context of the full-length modular
protein and would reveal additional sites of interaction. This would help us gain insights
into the physiological significance of this interaction in vivo, which is currently debated.
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METHODS
Purification of Soluble Mutant (Pal-) of GRK6
The soluble mutant of human GRK6, which lacks all the palmitoylation sites (soluble
GRK6 or sGRK6) was expressed and purified as described earlier [63] with the only difference
being that the last ion-exchange purification step was carried out on SP Sepharose (Pharmacia)
column instead of Source 15S.
Attempts to Isolate a Complex of sGRK6 with Ca2+·calmodulin
Lyophilized bovine calmodulin (Calbiochem) was reconstituted in 1 ml buffer consisting
of 20 mM Na-HEPES, pH 7.0, 100 mM NaCl, and 100 µM CaCl2 and stored at –20 ºC.
Calmodulin and sGRK6 (20 mM Na-HEPES, pH 8.0, 200 mM NaCl, 2 mM DTT) were mixed in
2:1 molar ratio and the reaction mixture was supplemented with CaCl2 to a 1 mM final
concentration. The protein mixture was incubated on ice for an hour before loading onto two
tandem Superdex 200 HR 10/30 columns (Pharmacia) pre-equilibrated with 20 mM Na-HEPES,
pH 8.0, 100 mM NaCl, 1 mM CaCl2, and 1 mM DTT. Under these conditions, we were not able
to demonstrate that GRK6 binds Ca2+·calmodulin (Fig. 25).
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Figure 25. Attempts to isolate a potential complex of sGRK6 with Ca2+·calmodulin
using size-exclusion chromatography.
A mixture of 1:2 molar ratio of the two proteins was loaded onto two tandem Superdex
200 columns in a running buffer containing 1 mM CaCl2. Calmodulin did not associate
detectably with sGRK6 as the two proteins elute in two separate peak fractions.
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Expression and Purification of Ca2+·Recoverin
The pTrec2 expression vector encoding bovine non-acylated (NA) recoverin was
purchased from American Type Culture Collection (ATCC).  The expression and
purification of NA-recoverin was carried out as described earlier [114] with a few
modifications in the protocol. Recoverin expression was enhanced when 250 ml DH5α
cells (100 µg/ml ampicillin) in Terrific broth (EMD) were grown (30 °C) in 2 L flasks
(instead of 1 L per flask) as this helps with efficient and uniform heating of the culture
during heat induction. After 4-5 hours of induction at 42-45 °C, cells were harvested by
centrifugation. The cell pellet was resuspended in ice-cold lysis buffer (10 ml/L of
culture) containing 50 mM Na-HEPES, pH 8.0, 10% glycerol, 5 mM EDTA, 1 mM DTT
and 0.1 mM PMSF (phenylmethanesulfonylfluoride) and was frozen in liquid nitrogen.
Thawed cell slurry was diluted in twice the volume of cold lysis buffer containing
0.1 mM PMSF. Cells were lysed by a single pass through Avestin C3 high pressure
homogenizer at 20,000 psi.  The first centrifugation was carried out for 20 minutes at
10,000 X g in a Beckman JA-17 rotor (4 ºC). Solid ammonium sulfate was added to the
supernatant to 65 % saturation while stirring the solution on an ice-bath. The solution was
stirred for one hour and the precipitated proteins were removed by centrifugation at
10,000 X g for 20 minutes in JA-17 rotor. The supernatant was collected and filtered
using a glass filter (Fisherbrand). Purification using Phenyl-Sepharose column
(Pharmacia) was skipped, as no significant purification was achieved using this column
in our hands. The filtered supernatant was dialyzed against 2 L dialysis buffer (20 mM
Na-HEPES, pH 8.0, 10% glycerol, 2 mM MgCl2, and 1 mM DTT) for a few hours and
then overnight against fresh 4 L dialysis buffer at 4 ºC (Fig 15A).  The dialyzed sample
(volume doubles during dialysis) was diluted 3-4 fold with fresh dialysis buffer to ensure
that conductivity of the solution was close to 5 mS/cm. The protein solution was loaded
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onto 7.85 ml Source Q column (Pharmacia) pre-equilibrated with dialysis buffer.
Majority of the contaminating proteins but not recoverin bind the Q column (Fig. 15B).
Amicon stirred cell (Millipore) with 10 kDa MWCO filter (Millipore) was used for
concentrating 600 ml of protein solution to about 50 ml which, was further concentrated
using a 30 kDa MWCO centriprep (Millipore) to about 10 ml. Protein was flash-frozen as
50 µl pellets in liquid nitrogen.
NA-recoverin was purified in batches (~ 1 ml at a time) on two tandem Superdex
75 HR 10/30 columns (Pharmacia) pre-equilibrated with NA-recoverin gel filtration
buffer (20 mM Na-HEPES, pH 8.0, 100 mM NaCl, 5% glycerol, 2 mM MgCl2, 1 mM
CaCl2, and 1 mM DTT). The molecular weight of the unmyristoylated recoverin was
estimated to be 28 kDa (calculated mass is 23.3 kDa) based on the elution of standard
proteins of known molecular weights (Bio-Rad) (Fig. 15C). Protein concentration was
quantified by Bradford (Bio-Rad) assay and 12% gels were used to assess the purity of
protein at various stages of purification. The yield of pure protein varied from 10 - 15
mg/L of culture.
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Figure 26. Purification of Ca2+·recoverin
(A) Gel representing purification by ammonium sulfate salting-out procedure.
Samples have been labeled from left to right as; (M) protein standards, (P1) pellet
fraction after lysis, (S1) supernatant fraction containing soluble protein after lysis, (P2)
pellet fraction from ammonium sulfate fractionation step, (S2) supernatant fraction post-
ammonium sulfate fractionation, (D) protein sample after extensive overnight dialysis.
(B) - (C) Purification of NA-recoverin on Source Q column. Even after extensive
dialysis and dilution of protein to lower the ionic strength of the solution, NA-recoverin
does not bind the column. The contaminating proteins are eluted in a 100 ml gradient of
0-200 mM NaCl (shown in green box, panel C). Samples have been labeled as: (M)
protein standards, (L) dialyzed and diluted protein loaded onto 7.85 ml Source Q column,
(FT) Flow-through of loading protein on Source Q column, (Fractions) fractions eluted
with a NaCl gradient (shown in green box in panel C).
D) Purification of NA-recoverin on gel filtration column.  1-2 ml of concentrated and
filtered protein (flow-through of loading on Source Q column) was loaded (labeled ‘L’ on
the gel) on two tandem Superdex 75 columns and eluted in running buffer containing 1




Isolation of Ca2+·recoverin·GRK1535-His6 Complex
GRK1535-His6 (Pool A) in 20 mM Na-HEPES, pH 7.5, 120 mM NaCl, and 1 mM
DTT was mixed with NA-recoverin (post size exclusion chromatography) in a 1:1.5
molar ratio. The protein mixture was incubated on ice for 30-60 minutes and then loaded
onto two tandem Superdex 200 HR 10/30 columns (Pharmacia) pre-equilibrated with
NA-recoverin gel filtration buffer (Fig. 16). Peak fractions containing Ca2+·recoverin·
GRK1535-His6 were pooled and concentrated using a 50 kDa MWCO centricon to 10
mg/ml and used for crystallization trials. The molecular weight of the peak containing the
complex is 80.5 kDa, which corresponds to a 1:1 complex of the two proteins. Excess
Ca2+·recoverin (NA-recoverin) elutes as a 28 kDa protein under the conditions used (Fig.
27). To demonstrate calcium dependence, the complex could not be isolated in the
absence of CaCl2 (data not shown).
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Figure 27. Isolation of Ca2+·recoverin·GRK1535-His6 complex on gel filtration
column.
A 1:1 complex (based on a standard run of proteins of known molecular weights) of the
two proteins was isolated by size exclusion chromatography (peak 1 on the
chromatogram). The fractions containing the complex that were pooled are marked with a
magenta colored box. The second peak contains excess recoverin.
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Attempts to Crystallize Ca2+·recoverin· GRK1535-His6  Complex
The protein complex was screened for crystallization at 4 ºC using commercial
screens (Hampton Research) in the presence of 2 mM MgCl2 and either 4 mM ATP or 4
mM AMPPNP  or in the absence of any nucleotide ligands. No crystal hits were obtained
under any of the crystallization conditions. Additional trays were set up to screen
different precipitating agents (polyethylene glycols, ammonium sulfate etc) under varying
range of pH, both at high (1 M) and low (200 mM) salt (NaCl). To ensure that the
complex does not dissociate during crystallization, 1 mM CaCl2 was also included in the
well solution. Thin, needle-like crystals appeared after 4 months and were grown using
protein pre-mixed with 4 mM ATP, pH 7.5 and 2 mM MgCl2 with the well solution
containing 15% PEG 8000, 200 mM NaCl, and either 100 mM Na-HEPES, pH 7.5 or 100
mM Tris-base, pH 8.0-8.5. These crystals were tiny and not harvested (Fig. 28).
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Figure 28. Crystals grown from drops containing Ca2+·recoverin·GRK1535-His6.
Tiny crystals nucleated in this drop after ~ 4 months and were not harvested.
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RESULTS
AIM 1. DETERMINE THE STRUCTURE OF Ca2+· CALMODULIN·GRK6
Attempts to isolate a complex of GRK6 with Ca2+·calmodulin
The calmodulin binding sites has been mapped to both the N- and the C-terminus
based on studies with GRK1, GRK2 and GRK5. In GRK5, the disruption of the C-
terminal site (site 2) lowers the sensitivity of the kinase whereas mutation of the N-
terminal site (site 1) alone has no significant effect on the IC50 of calmodulin [109]. The
binding sites for GRK6 have not been well characterized however based on the sequence
alignment it appears that it would bind calmodulin at structurally analogous sites to
GRK5 (Fig. 29). To try and isolate a complex of GRK6 with calmodulin, reactions were
set up such that there was 2-5 fold molar excess of calmodulin in the to reaction buffer.
The amount of calcium in different experiments was varied from 100 µM to 1 mM to
ensure that all the four Ca2+-binding sites were occupied. The same amount of calcium
was also included in the gel filtration buffer. Under these conditions, the two proteins did
not associate and eluted in two different peaks on a gel filtration column (Fig. 25). The
mass of the first peak was estimated to be 62.4 kDa (GRK6 is ~67 kDa) while the
calmodulin elutes in the second peak as a ~ 34 kDa protein (known mass of calmodulin is
16 kDa). GRK6 used was a soluble mutant of GRK6 wherein the three palmitoylation
sites at the C-terminus (Cys561, Cys562 and Cys565) were mutated to serine.
Considering the importance of site 2 in GRK5, it remains a possibility that palmitoylation
of the C-terminus of GRK6 could favor the binding to calmodulin. Also, because GRK5
has been used for most of the binding studies, in the future GRK5 should be tested for
calmodulin binding.
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Figure 29. Mapping of calmodulin binding sites in the GRK4 sub-family.
The GRK4 subfamily (GRK4, 5 and 6) is more potently inhibited by the calmodulin (IC50
is in nM range) compared to other GRKs [109, 115]. The N- (Site 1) and the C-terminal
(Site 2) calmodulin binding sites identified in GRK5 are colored green. The potential
palmitoylation sites mutated in the soluble mutant of GRK6 used in this study are colored
pink. The residues disordered in GRK6 structure [63] are colored grey, which also
includes C-terminal region spanning the “Site 2”.  The accession codes for the protein
sequences are: GRK4, AAI17321.1; GRK5, P43249; GRK6, P43250. The sequence
alignments were performed using the ClustalW program.
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AIM 2. DETERMINE THE STRUCTURE OF Ca2+·RECOVERIN·GRK1
Attempts to crystallize Ca2+·Recoverin·GRK1535 complex
Since the affinity of recoverin for GRK1 is not regulated by the presence of the
myristoyl group [82], the unmyristoylated recoverin was picked for structural studies as it
increases the solubility of the protein. A stoichiometric complex of GRK1535 (Pool A) and
non-myristoylated recoverin was isolated by size-exclusion chromatography in a Ca2+-
dependent manner (Fig. 27). Since GRK1 crystallization was facilitated by the addition of
nucleotides (apo form of the protein diffracts poorly and takes much longer to nucleate)
the complex was pre-incubated with 4 mM ATP or ADP or AMPPNP, pH 7.5 and 2 mM
MgCl2 prior to setting up the protein in trays. Trays were also set up in the absence of any
nucleotide ligand. Thin needle-like crystals appeared after ~4 months in drops containing
ATP (Fig. 28). These crystals were tiny and not harvested. Since autophosphorylation of
GRK1 has been suggested to weaken the interaction [82], it is possible that the complex
dissociates over time. The conditions need to be optimized to grow thicker crystals. This
could include varying the temperature, using a mutant of GRK1535 lacking all the
potential autophosphorylation sites and, use of a pure form of ADP, free of contaminating
amounts of ATP.
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Chapter 3. GRK6 and the Gα16 subunit
INTRODUCTION
GRKs can regulate G protein coupled signaling at the level of Gα subunits, in
addition to phosphorylating and thereby inhibiting the GPCRs. GRK2 is known to bind
Gαq, Gα11 and Gα14 subunits to block their interactions with the downstream effectors
[116-118] [61]. Pull-down assays using COS-1 cell lysates (unpublished data, Jeff
Benovic Lab, Thomas Jefferson University) suggested that GRK6 could bind the Gα16
subunit (another member of the Gαq family).
Project Goals
Determine the structure of GRK6·Gα16
The aim of this project was to isolate a complex of GRK6 and Gα16 for structural studies.
The first step was to overcome the problems associated with expression levels of Gα16
[119]. A chimera of Gα16 was thus designed the same way Gαi/q chimera was generated
[61]. The amino-terminus comprises of residue 1-28 of rat Gαq1 and the C-terminus
contains residues 40-374 of human Gα16.  Since the expression of functional Gα subunits
is enhanced in the presence of Gβγ, human Gαi/16 chimera was expressed as a
heterotrimer in insect cells.
- 110 -
METHODS
Cloning of Gβ1 Subunit into a pFastBac Dual Vector
A DNA template encoding bovine Gβ1 was prepared from the bovine Gβ1 virus (a
gift from Dr. Tohru Kozasa, University of Illinois at Chicago). The same Gβ1 virus was
earlier used for crystallization of GRK2 in complex with Gβ1γC68S [60]. The protocol
(Novagen) for preparation of viral DNA template is briefly described here. To a 0.5 ml
eppendorf tube containing 10 µl of high-titer Gβ1 virus stock (> 1 x 108 pfu/ml), 89 µl of
lysis buffer (10 mM Tris-HCl, pH 8.3, 0.45% Triton X-100, 0.45% Tween-20, 50 mM
KCl) was added. After adding 1 µl of Proteinase K (6 mg/ml in water, Invitrogen), the
reaction mixture was incubated at 60 ºC for an hour. This was followed by heat-
inactivation of Proteinase K (95 ºC for 10 minutes). The concentration of viral DNA
isolated is about 10 pg/µl. About 5 µl of Gβ1 viral DNA isolated was used as a template
in a 50 µl reaction to amplify Gβ1 coding fragment using Gbeta1for and revGbeta1
primers (Table 1). Pfu polymerase (Invitrogen) was used for amplification (35 cycles)
with the annealing temperature of 56 ºC.
Gβ1 fragment was ligated into the Sal I/Hind III sites of pFastBac Dual vector
downstream of the polyhedrin (PH) promoter of pFastBac Dual vector. Ampicillin-
resistant (100 µg/ml) clones in DH5α were picked and DNA sequence was verified
(DNA core facility, ICMB, University of Texas at Austin). Database search revealed that
the DNA sequence was homologous to rat Gβ1. A single point mutation in the rat coding
sequence, which changes aspartate 307 to a valine residue, makes the expressed protein
equivalent to the bovine sequence.
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Cloning of Gαi/16 Chimera into a pFastBac Dual Vector
Gαi/q viral DNA was first isolated from the Gα i/q virus (a gift from Dr. Tohru
Kozasa, University of Illinois at Chicago) following the protocol used to prepare Gβ1
viral DNA, and then used as a template to amplify a fragment encoding residues 1-28 of
rat Gαi1. The mutGi1forXmaI and rev28Gi1BglII primers (Table 1) were used for PCR
amplification with an annealing temperature of 60 ºC. The mutGi1forXmaI primer carries
a point mutation that changes glycine at position two in rat Gαi1 to alanine so that the
protein expressed does not undergo myristoylation.
Residues 37-359 of mouse Gαq in the Gαi/q chimera correspond to the residues 40-
374 of human Gα16. This fragment was amplified from the Gα16 cDNA (a gift from Dr.
Tohru Kozasa, University of Illinois at Chicago) using G16for40BglII and revG16KpnI
primers (Table 1). Annealing temperature used was 60 ºC.
Gαi1 (residues 1-28) and Gα16 (residues 40-374) fragments were both digested
with BglII and then ligated to generate a Gα i/16 chimera with BglII sequence at the
junction, which was also present in the functional Gαi/q chimera. The Gαi/16 chimera was
then ligated into the pFastBac Dual vector (encoding Gβ1 sequence) at the Sma I and Kpn
I sites downstream of the p10 promoter.
The recombinant pFastBac Dual vector has Gβ1 coding sequence downstream of
the PH promoter and Gαi/16 chimera cloned downstream of the p10 promoter (Fig. 30).
DNA sequencing revealed that the Gα i/16 chimera encodes a point mutation changing
glutamate residue 172 to alanine in the Gα16 sequence (E172A mutation was present in
the Gα16 cDNA). The Gαi/16β1γsol heterotrimer expressed using these clones will carry
E172A mutation in Gαi/16 subunit, which will be henceforth labeled as Gαi/16E172A.
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Figure 30. Cloning of Gαi1/16 chimera and Gβ1 into the pFastBac Dual vector.
The recombinant vector encodes Gβ1 and Gα i1/16 sequences downstream of the PH and p10
promoters respectively. The numbers (bottom panel) indicate the start of the restriction site
sequence (italicized and colored blue). Gαi1/16 chimera lacks a myristoylation site (G2A mutation





Expression and Purification of Gαi/16E172Aβ1γC68S Heterotrimer
Recombinant Gαi/16E172Aβ1γC68S protein was generated similarly to GRK1535-His6.
Six liters (8 x 750 ml) of High Five cells (2 x 106 cells/ml) in 2 L baffled flasks were co-
infected with 20 ml of Gαi/16E172Aβ1 and 15 ml of His6-Gγ2 viruses. The His6-Gγ2 virus
contains a C68S mutation [120] that encodes a soluble mutant of Gγ2 (GγC68S). Cells were
incubated in a 28 ºC shaker at 140 rpm and harvested approximately 36 hours after viral
addition by centrifugation at 1000 X g for 15 minutes at 4 °C in a Beckman JLA 8.1000
rotor. Cell pellet was flash-frozen in liquid nitrogen and stored at -80 °C. The
heterotrimer was purified on a Ni2+-NTA (Qiagen) column as described earlier [61]. The
samples were visualized on SDS-PAGE and fractions containing the Gαi/16E172Aβ1γC68S
heterotrimer were pooled and concentrated using 50 kDa MWCO centriprep.
Activation of Gαi/16E172A Subunit and Complex Studies With sGRK6
The alpha subunit was first activated before incubating it with GRK6. About 2 mg
of dialyzed Gαi/16E172Aβ1γC68S (in 20 mM Na-HEPES, pH 8.0, 100 mM NaCl, 1 mM MgCl2,
50 µM GDP, pH 8.0, and 5 mM DTT) was mixed with activation buffer containing 20
mM Na-HEPES, pH 8.0, 100 mM NaCl, 25 mM MgCl2, 1.5 mM EDTA, pH 8.0, 500 µM
GTPγS, pH 8.0, and 1% cholate in a 100 µl reaction. Unlike Gαq, Gα 16 cannot be
activated by addition of GDP and Al3+, Mg2+ and F−. Instead, it needs GTPγS, as shown
for its ability to activate PLC-β1 [119]. The heterotrimer was incubated at 30 ºC for 30
minutes. Assuming that about one-third of the heterotrimer solution is activated
Gαi/16E172A subunit, an equimolar amount of sGRK6 (1.27 mg in 20 mM Na-HEPES, pH
8.0, 200 mM NaCl and 2 mM DTT) was added and the reaction mixture was incubated
for 15 minutes at 30 ºC. The final concentrations of MgCl2, EDTA, GTPγS and cholate in
approximately 500 µl reaction volume were 5 mM, 0.3 mM, 100 µM and 0.2%
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respectively. The protein mixture was loaded onto a single Superdex 200 HR 10/30
column (Pharmacia) pre-equilibrated with Gαi/16E172A gel filtration buffer (20 mM Na-
HEPES, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 10 µM GTPγS, and 1 mM DTT). Under
these conditions, Gαi/16E172A did not associate with sGRK6. The potential problems were
the presence of significant amounts of contaminating β1γC68S subunits and 0.2% cholate in
the final reaction mixture. Hence, the protocol to purify Gα i/16E172A was modified to
address these problems.
Isolation of Activated Gαi/16E172A Subunit on Ni2+-NTA Column
The goal was to first isolate pure and activated form of Gαi/16E172A subunit and then
use it for complex formation. The High Five cell pellet infected with the heterotrimer was
lysed as described above and loaded onto a 10 ml Ni2+-NTA drip column. After washing
the column with 20 column volumes each of Gαi/16E172Aβ1γC68S Buffer A (20 mM Na-
HEPES, pH 8.0, 100 mM NaCl, 1 mM MgCl2, 50 µM  GDP, pH 8.0, and 10 mM β-
mercaptoethanol) and Buffer B (Buffer A containing 300 mM NaCl, and 10 mM
Imidazole, pH 8.0), the column was incubated at room temperature for about 15 minutes
in Gαi/16E172A elution buffer (20 mM Na-HEPES, pH 8.0, 300 mM NaCl, 50 mM MgCl2,
50 µM GTPγS, 10 mM CHAPS, and 10 mM β-mercaptoethanol). Activated Gαi/16E172A
was eluted in 1 ml fractions with 10 ml of room temperature Gαi/16E172A elution buffer.
Bound Gβ1γC68S was eluted with a buffer containing 20 mM Na-HEPES, pH 8.0, 300 mM
NaCl, 50 mM MgCl2, 50 µM  GDP, 150 mM Imidazole, pH 8.0, and 10 mM β-
mercaptoethanol (Fig. 31A). Fractions containing activated Gαi/16E172A were pooled and
concentrated to about 4 mg/ml using 50 kDa MWCO centricon (Millipore) and loaded
onto a single Superdex 200 HR 10/30 column (Pharmacia) pre-equilibrated with
Gαi/16E172A gel filtration buffer (20 mM Na-HEPES, pH 8.0, 100 mM NaCl, 5 mM MgCl2,
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10 µM GTPγS, and 1 mM DTT). Gαi/16E172A elutes in a single sharp peak as a ~52 kDa
protein (Fig. 31B)
Purified Gαi/16E172A (490 µg) and sGRK6 (770 µg) were mixed in Gαi/16E172A gel
filtration buffer containing 50 µM GTPγS. The mixture was incubated on ice for 30
minutes and loaded onto a single Superdex 200 HR 10/30 column (Pharmacia) pre-
equilibrated with Gα i/16E172A gel filtration buffer. The two proteins elute in two
overlapping peaks and attempts to isolate a complex under these conditions were not
successful (Fig. 31C).
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Figure 31. Purification of activated Gαi/16E172A from the heterotrimer and the
complex formation with sGRK6.
(A) Ni2+-NTA affinity purification. The Gγsol subunit is expressed as a His6-tagged
protein. The samples have been labeled from left to right as: (M) protein standards, (1)
pellet fraction after lysis, (2) supernatant fraction containing soluble protein after lysis,
(3) flow-through of supernatant loaded onto nickel column, (4) column wash with Buffer
A, (5) column wash with Buffer B, (6)-(17) Gαi/16E172A protein eluted with Gα i/16E172A
elution (activation) buffer, and (18) bound Gβ1γC68S eluted with the elution buffer
containing 150 mM imidazole.
(B) Size-exclusion chromatography of activated Gαi/16E172A. Fractions (lanes labeled 6-
14) from step (A) containing activated Gα i/16E172A were pooled and concentrated and
purified on a single Superdex 200 HR 10/30 column (Pharmacia) pre-equilibrated with
Gαi/16E172A gel filtration buffer
(20 mM Na-HEPES, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 10 µM GTPγS, and 1 mM
DTT). Samples on the gel have been labeled as: (M) protein standards, (L) pooled and
concentrated sample of activated Gαi/16E172A loaded onto the column, and the peak
fractions.
 (C) Attempts to isolate a complex of Gα i/16E172A and sGRK6. Activated Gα i/16E172A
subunit from step (B) was concentrated and mixed with sGRK6 in a 1.5:1 molar ratio.
The protein solution was supplemented with GTPγS to a final concentration of about 50
µM. The samples have been labeled as: (M) protein standards, (L) mixture of Gαi/16E172A





AIM 1. DETERMINE THE STRUCTURE OF GRK6·Gα16
The Gα16 subunit used in these studies was a chimera (Gα i/16) wherein the N-
terminus of Gα16 was replaced with that of Gαi1. The yield of Gα 16 chimera was
enhanced over that of wild-type protein expressed in baculovirus-infected insect cells,
and was estimated to be about 750 µg/L of cell culture. This is significantly higher than
the published expression levels of a non-chimeric Gα16 subunit (~18 µg from six liters of
insect cells) [119]. We were also able to modify the purification protocol to generate the
activated form of the Gα16 subunit (Fig. 31), free from contaminating amounts of Gβγ
subunits. However, the attempts to isolate a complex of activated Gα16 and GRK6 by size
exclusion chromatography were not successful. The project was initiated taking the lead
from the lab of Jeff Benovic (Thomas Jefferson University; unpublished data) who
provided preliminary evidence for the two proteins to associate based on pull-down
assays using crude COS-1 cell lysates. We were using purified proteins and the fact that
they did not associate in our assays suggests that the interaction could be indirect, or in
fact an artifact.
DNA sequencing revealed that the Gα16 subunit carries a point mutation (E172A).
This residue is either glutamate or aspartate in all the other Gα16 sequences. Structural
comparison with Gαq suggests that the mutation lies in a solvent exposed αE-αF loop
and would not affect the folding of Gα 16 (Fig. 32). Size exclusion chromatography
confirms that the protein (Gα16E172A) is not misfolded (Fig. 31B). The mutation does not
overlap with the GRK2 binding site mapped on Gαq, which involves α2, α3 and α3-β5
loop.
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Figure 32. Structural alignment of the Gαq family members.
The numbers on top of the sequence alignment indicate residue numbers in the Gαq
sequence. The secondary structure assignment (yellow bars represent α-helices and
orange arrows for β-sheets) is based on the Gαq structure (PDB code 2BCJ) [61]. The
blue boxes represent the three switch regions in the Gα subunits. The E172 residue
mutated in the Gα16 chimera is colored red. All the sequences are mouse except Gα16,
which is human. The accession codes for the protein sequences are: Gαq, AAA63306.1;
Gα11, NP_034431.1; Gα14, NP_032163.2; Gα16, AAA35860.1. The sequence alignments
were performed using the ClustalW program.
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Chapter 4. Discussion
A model for Rho* Docking
Peptides derived from the cytoplasmic tail (C-tail) of rhodopsin are poor
substrates and their phosphorylation by GRK1 is enhanced in the presence of Rho* by ~
100-fold [40, 76, 77] suggesting that receptor docks at site(s) other than the C-tail. In
addition, peptides derived from various cytosolic loops compete with rhodopsin for
GRK1 suggesting that the cytoplasmic loops of Rho* are involved in binding [41, 52].
The rhodopsin binding surface on GRKs, however, is not well characterized but is
thought to involve the amino-terminus of GRKs [45, 49, 57], which is revealed in one of
the structures of GRK1. The conformation of the N-terminus appears to be stabilized by
the crystal contacts mediated by the loop connecting the αN and α0 helices (Fig. 14c).
The symmetry related loop docks in the canyon lined by the αN helix, the small lobe and
the “tail-loop” of the C-terminal extension and could mimic the interactions between
receptor and GRK1 during signaling events.  Comparison of GRK1 structure with those
of PKA and PKB reveals that the “tail-loop” in GRKs is 4 residues shorter (Fig. 22b)
forming a solvent exposed canyon. The αN helix of the N-terminus and the active site
tether of the C-terminal extension form the walls of this canyon, with the hinge of the
kinase domain resting at the bottom (Fig. 33a). The canyon is lined by several
hydrophobic residues that are conserved in all the GRKs.  We expect Rho* to dock at this
site. In our model (Fig. 33b), the third cytoplasmic loop of Rho* is modeled to engage the
docking site as site-directed mutants in this loop have been shown to affect transducin
activation and phosphorylation [52, 79]. The C-tail of Rho* was modeled that such it
binds to the large lobe of the kinase domain in a manner similar to the way peptides bind
PKB [121].  In this model, the membrane proximal surface of GRK1 is relatively flat and
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is lined by both positively charged and hydrophobic residues. Similar orientation has
been predicted for other GRKs [60, 61, 63]. In this orientation, the GRK1 active site is
accessible to other molecules of Rho or Rho* in the same membrane plane, allowing
high-gain phosphorylation [122, 123] and would allow for multiple rounds of nucleotide
exchange on GRK1 while Rho* is engaged in the docking site.
Rho*-meditated Activation of GRK1
The binding of nucleotide ligands stabilizes the kinase domain of GRK1 [52] as is
evidenced by the conformational flexibility of the kinase domain in apo-GRK1 structure.
Nucleotide-binding is associated with the ordering of different elements of the kinase C-
terminal extension that packs adjacent to the nucleotide-binding pocket. However, even
though nucleotide binding induces a ~8° closure of the kinase domain, an additional
closure of ~15° is still needed to properly align the two lobes of the kinase domain to
resemble the active PKA structure [96] (Table 5) The glycine-rich P-loop, which makes
contact with the phosphate tail of the nucleotide is shifted up from the nucleotide-binding
pocket and resembles the structure of P-loop in the  apo structure of PKA [101]. Since the
kinase C-terminal extensions lies close to the P-loop in the structure and also contributes
to the putative receptor docking site, we hypothesize that receptor binding might induce
the additional domain closure needed along with the reorientation of the P-loop to
resemble the activated structure of PKA [96, 99] (Fig. 34).
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Figure 33. A model of Rhodopsin docked to GRK1.
(a) A close-up of the proposed receptor docking canyon (see Fig. 22b). The conserved
hydrophobic residues forming the walls of the canyon are indicated. (b) GRK1 is
rendered as spheres and the view is rotated 180° around the vertical axis from panel (a).
The RH domain is colored magenta, the kinase domain yellow, and the N-terminus and
kinase C-terminal extension are green. A model of an array of rhodopsin molecules (PDB
1N3M) was docked such that loop 3 of Rho* (red) lies in the proposed “docking canyon”.
Only two rhodopsin molecules from this array have been shown for clarity. Using PKB
peptide (PDB 1O6L) as a guide, the C-tail Rho peptide (cyan) was modeled such that the
Ser338 residue is close to the γ-phosphate of ATP in the active site. With these
constraints, the active site is accessible to the C-tail of either Rho* or a neighboring
inactive Rho (brown) in the same membrane plane.
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Figure 34. A schematic representation of Rho*-mediated activation of GRK1.
Upon light stimulation, the chromophore 11-cis-retinal is isomerized to all-trans-retinal
resulting in an active conformation of rhodopsin (Rho*), which stimulates transducin
activation. The RH domain of GRK1 is colored violet and the kinase domain is yellow.
The N-terminus of GRK1 in the apo state is disordered in this model and we predict that
it becomes ordered (dark green helix) when bound to Rho*/lipid-bilayer or
Ca2+·recoverin. The nucleotide-binding induces a 8° closure of the kinase domain, but
additional closure is expected when the third cytosolic loop of Rho* docks in the putative
docking canyon. The C-tail of Rho* or a neighboring inactive Rho is phosphorylated
creating a binding site for arrestin. The retinal molecule is recycled and binds to the opsin
moiety to regenerate Rho.
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Mutagenesis Studies
GRK1 structure and mass spectral analysis revealed that the N-terminus of GRK1
was phosphorylated at several previously unidentified sites (Ser5 and Thr8). Our in vitro
assays suggest that phosphorylation at these sites is not required for rhodopsin
phosphorylation. However, they could play a role in functions other than direct
interaction with receptor, such as stability or the localization of the kinase in the rod cells.
Phosphorylation has been shown to affect the activity, localization and protein-protein
interactions in case of several proteins. For example, phosphorylation of nitrate reductase
and cytosolic pyruvate kinase has been suggested to target them for degradation [124].
 The dimerization mediated by the RH domain in crystals has been previously
reported for GRK6, and, as for GRK6, the residues at this interface in GRK1 are not
required for rhodopsin phosphorylation in our in vitro assays [63]. Modeling studies
using a different rotamer of W531 residue suggests that dimerization could be resulting
from a short domain-swap occurring at high protein concentrations during crystallization.
However, considering the extent and the conservation of the interface and the role of RH
domains serving as protein-binding surfaces in several other proteins [59, 61, 125], it
remains possible that this interface could mediate interaction with as of yet unidentified
protein target(s) in vivo.
Recoverin Binding
Although the physiological relevance of the recoverin-GRK1 interaction is
debated [110, 112],  comparison of our GRK1 structure with that of the recently
determined N-terminal peptide of GRK1 (residues 1-25) in complex with Ca2+·recoverin
[126] suggests a mechanism by which recoverin can inhibit GRK1 function in vitro.  The
ordered portion of GRK1 in the recoverin bound structure extends from residue 4 through
16 with GRK1-Val9, Val10, Ala11, Ala14 and Phe15 binding to a hydrophobic surface
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on recoverin.  In our structure the αN forms a helix from residues 12-25, and both Val9
and Phe15 pack against the RH domain. This suggests that recoverin binding would
inhibit receptor phosphorylation by sterically blocking the interaction of N-terminus of
GRK1 with the lipid-bilayer/micelles or the receptor itself.
Molecular basis of Oguchi Disease
Defects in rhodopsin kinase can lead to Oguchi disease in humans (Fig. 35). A
number of mutations have been identified in several patients that suffer abnormal
recovery kinetics of rod photoreceptors [84]. Patient with heterozygous mutations in the
two alleles bearing a point mutation V380D in exon 5 (Val377 in bovine GRK1) and a
Ser-536 (4-bp del) suffers prolonged dark adaptation. The Val377 residue is a buried
residue in the αF helix, and mutation to negatively charged Asp would likely destabilize
the fold of the kinase domain. The frameshift mutation Ser-536 (4-bp del) resembles the
soluble bovine GRK1 (spanning residues 1-535) we used for structural studies and is two
amino acids longer. The unaffected family members of the patient were found to be
carriers of one of the two mutations and were normal. Another patient was found to be
homozygous for deletion of residues 357-398 (residues 354-395 in bovine GRK1) in the
exon 5 that would result in a loss of αEF1, αEF2 and αF helices and the αF-αG loop in
the large lobe of kinase domain. These regions help constitute the peptide-binding
channel. In addition, a frameshift mutation results in a premature truncation 18 codons
downstream leading to a more lethal disruption of the kinase domain. Recently, a
missense mutation P391H [86] in GRK1 affecting the cone recovery kinetics was
reported in two Japanese siblings. The Pro391 residue (Pro388 in bovine sequence) in the
αF-αG loop of the kinase domain is conserved in all the GRK sub-families. The
substitution of proline by histidine would introduce polarity and size differences that are
likely to result in steric clash with neighboring hydrophobic residues.
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Figure 35. Mapping of Oguchi causing mutations on the GRK1 structure.
(a) Teal colored sphere represents the V377 residue (V380 in humans) in αF helix that is
mutated to an aspartate residue. The frameshift mutation Ser536 (4-bp del) in the second
allele results in a truncated protein that is 2 residues longer than GRK1535 protein. (b) The
residues 354-395 (357-398 in humans) deleted are colored teal and the region deleted as a
result of the frameshift mutation is colored black. (c) Teal colored sphere represents the
P388H mutation (P391 in humans).
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Future Directions
Based on the information revealed in different GRK1 structures we have proposed
a testable hypothesis for receptor-mediated activation of GRKs. Mutational analysis of
the putative docking canyon in GRK1 would confirm if the residues are implicated in
receptor function. The studies could be translated to other GRK sub-families as well to
reveal a conserved model of receptor-mediated activation. The structure of a complex of
GRK1·recoverin could reveal additional sites of interaction that could include the surface
on the RH domain that mediates dimerization. This would lend further insights into the
physiological significance of this interaction, which is currently debated. Even though it
may need different crystallization conditions, the structural analysis of L166K mutant of
GRK1 would confirm if dimerization at higher concentrations in crystals is resulting from
a domain-swap. Finally, the structure of Rho* bound to GRK1 would reveal the
mechanism by which GRKs recognize activated GPCRs and are in turn activated.
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Appendix
Attempts to Crystallize Components of the Mre11/Nbs1/Rad50 Complex
Spodoptera frugiperda sf21 insect cells were co-infected with baculoviruses
encoding human Mre11 and Nbs1 in Dr. Tanya. Paull’s laboratory (University of Texas
at Austin). Several constructs of the two proteins were expressed and purified:
• Wild-type Nbs1 and His6-human Mre11 (R633stop, ~70 kDa)
• FLAG-tagged Nbs1 and hMre11-His6 (Δ376-708)
• Rad50 mutant, Rad50Δcc lacking all the coiled coil domains (residues 209-1117 are
replaced with a seven amino acid insertion that forms a loop) with His6 tag at the N-
and C-terminus.
All the purified Mre11 and Nbs1 constructs used were not stable in solution.
Inclusion of CHAPS and glycerol in the buffers did not keep the protein stable
(precipitation of protein when at a concentration ~ 1 mg/ml).  The Rad50Δcc construct
was the only protein that could be concentrated to about 10.5 mg/ml but high salt (500
mM NaCl) conditions were needed to keep it in solution. The yield of this mutant was
estimated to be about 1 mg/L of cell culture. Crystallization trays were set up screening
different precipitating agents at varying range of pH. No protein crystals were observed.
Further crystallization conditions were not explored.
To overcome protein solubility problems different domains of Mre11 and Nbs1
were expressed as Maltose Binding Protein (MBP) fusion proteins using the E. coli strain
Rosetta (DE3) pLysS. These were the well-folded regions of the protein based on the
sequence alignment of various eukaryotic proteins and included the catalytic domains of
the protein.
- 129 -
The various hMre11 fragments expressed in Rosetta cells express in milligram
quantities (2-4mg/L). However, post digestion with TEV protease the protein was not
soluble even in the presence of 1 mM MnCl2. Mn2+ is essential for the exonuclease
activity of Mre11 [127] and was added to all the buffers to help stabilize the protein.
Also, the purified Mre11 constructs could not be concentrated to 1 mg/ml. All the Nbs1







(The numbers in the parentheses indicate the length of the protein fragments
cloned).
Another problem with the Mre11 constructs was that the fusion-protein could
either not be cleaved with TEV protease or the protein underwent proteolysis from the C-
terminus. The only construct that looked promising was Nbs1(620-754), but the yield of
purified protein was only 200 µg from six liters of E. coli culture. Attempts to co-purify
Mre11 and Nbs1 fragments in order to stabilize the individual protein components also
failed.
One potential reason for TEV protease not cleaving the fusion protein efficiently
was the presence of a bulky phenylalanine residue (residue 13 in Mre11 sequence) in the
vicinity of the TEV recognition sequence. Hence, new Mre11 constructs were designed to
contain the entire amino-terminus. The strategy was to co-express Mre11 and Nbs1
constructs in insect cells in order to keep the proteins stable.  Based on sequence
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alignments, two Mre11 constructs were designed: M489 (residues 1-489) and M402
(residues 1-402) which, encode the phosphodiesterase motif of the nuclease domain of
Mre11. The two fragments were ligated into the EcoRI/SalI sites downstream of the
Polyhedrin promoter of pFastBac Dual-His6. Nbs1 fragment (residues 620-754, N620)
was ligated into the NcoI/XhoI sites of p10 promoter of the same vector that encodes
Mre11 fragment. Both the Mre11 fragments bear a non-cleavable C-terminal His6-tag.
Baculoviruses were generated using the Bac-to-Bac Baculovirus Expression System
(Invitrogen).
For the purification of the two Mre11/Nbs1 constructs expressed in High Five
cells, one liter of (2 x 106 cells/ml) insect cells were infected with 25-30 ml of either the
M489/N620 or M402/N620 baculoviruses and harvested 36 hours post viral addition.
Thawed cells pellets were resuspended in 40 ml lysis buffer (50 mM Na-HEPES, pH 8,
500 mM NaCl, 10% glycerol, 0.5% Tween 20, and 20 mM b-mercaptoethanol)
containing EDTA-free protease inhibitor cocktail (Roche) per liter of cells. Cells were
lysed the same way GRK1535-His6 infected cells were processed (refer to section XX).
Clarified supernatant was loaded onto a 5 ml Ni2+-NTA drip column (Qiagen) pre-
equilibrated with lysis buffer. After washing the column with 10 column volumes each of
lysis buffer and wash buffer (lysis buffer containing 20 mM imidazole), the bound
protein was eluted as 1 ml fractions in elution buffer (lysis buffer containing 150 mM
imidazole). Fractions containing M489/N620 or M402/N620 complex were pooled and
dialyzed twice for one hour each time at 4 °C against a buffer containing 25 mM Na-
HEPES, pH 8, 100 mM NaCl, 10% glycerol, and 1 mM DTT. A slight precipitation in the
protein solution was observed during dialysis and it was removed by filtration. The
filtered protein was then purified on a 7.85 ml Mono Q column (Pharmacia) pre-
equilibrated with QA buffer (dialysis buffer). The complex elutes at an approximate ionic
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strength of 200 mM NaCl in a 60 ml gradient of 0-60% QB buffer (QA buffer containing
1M NaCl) at a flow rate of 2 ml/min. The 1 ml fractions containing the protein complex
were pooled and concentrated using a 50 kDa MWCO centricon (Millipore). The last
purification step was gel filtration chromatography. The concentrated protein sample
from the Mono Q purification step was filtered and loaded onto tandem Superdex 200 HR
10/30 columns (Pharmacia) pre-equilibrated with QA buffer at a flow rate of 0.3 ml/min.
The protein complexes elute at 24-25.5 ml of buffer QA with an approximate molecular
weight of 200 kDa as a higher order complex (the expected molecular weight of a 1:1
complex is ~72 kDa). A 12% gel was used to monitor the purity of protein at various
stages of purification. The pooled protein fractions (75-80% pure) were concentrated to
about 5 mg/ml with an estimated recovery of about 85%.
The protein complex (M489/N620) was functional in endonuclease assays using a
hairpin DNA oligo as a substrate:
5’                                      CATCCATGCCTACCTGAGTACCAGTAG
                       3’CAGCTAGACCGTAGGTACGGATGGACTCATGGTCATC
Determine the Atomic Structure of human Mre11 (M/R/N) Complex
To gain further insight into the functioning of the human Mre11 complex,
Mre11/Nbs1 complexes (from 1) were co-expressed in High Five cells along with
deletion mutant(s) of Rad50. Active Rad50 mutants that also bind the wild-type
Mre11/Nbs1 complex were picked. The complex was purified similarly to the
purification of M/N constructs from High Five insect cells. The expression was poor and
the protein complexes could not be purified to homogeneous levels. Several other
combinations of various constructs of the three proteins were tested in High Five and sf21
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cells but the levels of protein expression were low. Some of the combinations tested
were:
• M489/N620/Rad50Δcc2 (mutant containing two copies of the seven amino acid
insertion)
• M402/N620/ Rad50Δcc2
• His6-human Mre11 (R633stop)/Nbs1/Rad50
• Mre11/Nbs1/ Rad50Δcc4 (contains four copies of the seven amino acid insertion)
• Mre11 (ATLD)/Rad50
• Human Mre11(ATLD1/2)/R
• Wt yeast Mre11/Rad50 complex
• Mre11 :221(5) human R633 stop mutant
                     296(5) C-ter His tag  Δ376-708
• Nbs1 40(2) human wt FLAG-tagged
                  328(10)
• Rad50 543(15) Rad50Δcc2
                    469 = Rad50Δcc
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